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Sharon E. Groover 
 
Huntington’s Disease (HD) is a genetic, neurodegenerative disease characterized by an 
abnormal polyglutamine (polyQ) expansion in the first exon of the huntingtin protein 
(htt). The polyQ domain facilitates aggregation and initiates the formation of a diverse 
collection of aggregate species, including fibrils, oligomers and annular aggregates. The 
first 17 amino acids of htt (Nt17) directly flank the polyQ domain and is a key factor in 
htt’s association to membranous structures. In addition to Nt17 being an amphipathic α-
helix, it also promotes aggregation through self-association and contains numerous 
posttranslational modifications (PTMs) that can modulate toxicity and subcellular 
localization.  For in depth understanding of these mechanisms, particularly in the 
presence of lipid membrane surfaces, the PTM phosphorylation and macromolecular 
crowders found in subcellular environments were explored. Through the application of 
phosphomimetic mutations of htt to a variety of lipid systems, lipid-specific impacts of 
electrostatic interactions involved in htt/lipid interactions were elucidated. Cytosolic 
conditions mimicked through the addition of macromolecular crowders and htt were 
evaluated at both solid/liquid and membrane/liquid interfaces, with each crowder having 
a distinct effect on htt aggregation. The results presented here aid in the understanding 
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1. Introduction: Role of the Structure and Functions of the 
Huntingtin Protein Related to Huntingtin’s Disease 
 
 
1.1 General Protein Misfolding Diseases 
 A hallmark of several neurodegenerative disorders is the systematic buildup of 
micron sized proteinaceous material in tissues and cellular compartments. These 
diseases include Parkinson’s Disease (PD), Alzheimer’s Disease (AD) and Huntingtin’s 
Disease (HD). Clinical symptoms include impaired cognitive function and motor control 
and pathological changes comprise of synaptic abnormalities and neuronal cell loss.1–3 
In each of these diseases, a hallmark is the conformational change of specific proteins 
inducing aggregation and accumulation of amyloids within the brain.4–6 These insoluble 
amyloids are identified through their cross-β sheet rich structures and fibril 
morphologies.7,8 These general amyloid disorders are also classified as protein 
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Figure 1.1: Amyloid structure in HD. Diseased neurons within HD patients’ brains contain 
amyloid plaques which are comprised of a variety of structures stemming from the disordered 
protein, leading eventually to amyloid fibrils. These plaques are localized to the nucleus of the 
neuron. Beginning with the disordered protein, when misfolded, β-sheet structures (as shown by 
grey arrows) start to form. The misfolded proteins reach a critical nucleus and form an amyloid 
intermediate that eventually forms the β-sheet rich amyloid fibrils. Created in part with 
BioRender.com 
 
 The driving force behind protein folding is the tendency of hydrophobic residues 
to sequester together within the protein interior due to a phenomenon known as the 
hydrophobic effect.9  Functional proteins are newly synthesized from linear chains of 
amino acids and conform to a well-defined three dimensional compact structure of 
minimal energy, consistent with the concept of a folding energy landscape funnel (Fig. 
2).10 In this compact, native conformation, the hydrophilic residues are located on the 
protein surface and exposed to water. The pathway along the energy landscape leading 
to the native conformation contains local energy minima in which partially folded 
intermediates can become trapped.11–13 These intermediates risk misfolding and 
following alternative folding pathways leading to structures differing from the native 
conformation. In amyloidogenic proteins, these alternative intermediates lead to β-sheet 
rich monomeric or multimeric structures such as oligomers that can further promote the 
formation of fibrils, or amorphous aggregates.14 These altered conformations associated 
with amyloid result in affected biological properties and a toxic gain of function.15,16 
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Figure 1.2: Protein folding funnel energy landscape. Unfolded proteins generally undergo a 
variety of conformations to react the most compact and stable native state (green pathway). If 
the unfolded protein proceeds through an alternate pathway other than the native folding 
pathway by becoming trapped in energy minima, misfolded intermediates are formed (purple 
pathway). For amyloid proteins, these misfolding intermediates are β-sheet rich and continue to 
form amyloid aggregates of lower energy, with increasing β-sheet content. Created in part with 
BioRender.com 
 
1.2 Huntington’s Disease and the Role of the Huntingtin Protein 
 Huntington’s Disease (HD) is a fatal, autosomal dominant neurodegenerative 
disease that results in dystonia, chorea, and loss of cognitive abilities.17,18 This disorder 
results from a mutation in the HTT gene found on the short arm of chromosome 4, 
which codes for the huntingtin protein (htt). The mutation is a CAG trinucleotide 
expansion, which codes for the amino acid glutamine (Q). Therefore, the expansion in 
the translated huntingtin (htt) protein is referred to as the polyglutamine (polyQ) domain, 
and this domain is located near the N-terminus of htt.19 HD is one of ten identified CAG-
repeat or polyQ disorders. In these diseases, including HD, there is a high correlation 
between age of onset, polyQ length, and aggregation of proteins containing expanded 
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polyQ.20,21 While the polyQ domain is normally ~17-20 residues long in htt, a polyQ 
repeat length of ~35 is the critical threshold associated with HD, and disease severity 
increases as the polyQ length expands (Fig. 3).19,22–25  
 
Figure 1.3: Huntingtin protein, exon1 and polyQ thresholds. An abnormal trinucleotide 
(CAG) repeat length within the IT15 gene is the root cause of htt’s pathogenicity. The first exon 
at the N-terminus, known as exon1, contains three distinct domains, Nt17 (green), polyQ 
(purple) and a proline rich domain (polyP) (grey). As the polyQ length increases, age of onset 
decreases, with the intermediate region indicating that disease will occur later in life (triangle).  
 
 The exact mass of htt is dependent upon the size of the polyQ domain, however, 
the full length of htt is comprised of 3144 amino acids, 67 exons and is ~350 kDa.19 The 
polyQ domain follows is located in the first exon of htt and is preceded by 17 amino 
acids commonly referred to as Nt17.  Beyond Nt17, the polyQ domain is flanked in 
exon1 on the C-terminal side by a proline-rich domain that contains two polyproline 
(polyP) stretches. The flanking domains have varying roles. Nt17 initiates lipid binding 
and aggregation,26–30 and the polyP domain modulates htt-lipid interaction26 and htt 
nucleation.31 Evidence suggests that N-terminal fragments comparable to exon1 are 
directly involved in HD,32–37 thus many studies have been completed with biologically 
relevant N-terminal htt fragments.  Htt-exon1 is responsible for increased aggregation 
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and accrual of proteinaceous material in the striatum in HD patients,38 and it is a stable 
fragment that is continuously produced in the brain through proteolysis of full-length 
htt.32 N-terminal fragments comparable to htt-exon1 are detected in knock-in mouse 
models expressing full length htt32, resulting in similar progressive neurological 
phenotypes and age-dependent accumulation.33,38,39 Evidence suggest the use of htt-
exon1 is an ideal model for physiologically relevant, in vitro biophysical studies of 
oligomers and fibrils formed by purified htt-exon1, as htt-exon1 is responsible for 
increased aggregation and accrual of proteinaceous material in the striatum in HD 
patients.38  
1.3 Mechanisms and Toxicity of Aggregation 
 Similar to other neurodegenerative diseases, fibrils in HD form via a nucleation 
dependent polymerization growth pathway. Though the details of aggregation fluctuate 
for each protein, proteins containing expanded polyQ tracts tend to follow the basic 
polyQ-mediated aggregation schemes.14 Mutant htt assembles into a collection of 
various aggregates associated with amyloid diseases, such as fibrils, oligomers, annular 
structures, inclusion bodies and amorphous aggregates.20,40–42  
A rate limiting43,44 nucleation phase, known as the lag phase, is associated with 
the alteration of the native structure of the protein to non-native conformations.45 A 
mono- or multimeric nucleus formed in the lag phase through several inter- and 
intramolecular forces causes the rapid elongation of β-sheet rich fibrillar 
structures.44,46,47 There are two dominant aggregation pathways of generic polyQ 
aggregation: a) direct nucleation from monomer to fibril48 and b) the reordering of 
soluble oligomeric structures into β-sheet rich fibrillar structures.42 These two 
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mechanisms are not mutually exclusive; however, conditions that promote 
oligomerization as the dominant or “on pathway” aggregation pathway accelerate the 
process.14  
 
Figure 1.4: Schematic model of htt aggregation pathways. Htt aggregation follows three 
main aggregation pathways, which begin with a misfolded, non-native conformation of a 
monomer (green). On pathway mechanisms eventually lead to the formation of β-sheet rich 
fibrils, by direct transition of misfolded monomer to fibril (bottom), or through a nucleation 
mechanism resulting in oligomeric species (second from bottom, circle). Off-pathway 
mechanisms include the formation of oligomers, amorphous and annular aggregates (top and 
second from top, pink). These pathways are not mutually exclusive, and together the various 
aggregates can form large inclusions (bottom right) seen in HD patients’ brains. Reprinted from 
Adegbuyiro, et al. Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative 
Disease. Copyright 2017 American Chemical Society.  
 
The aggregation mechanisms can result in an assortment of aggregates co-
existing, but there is limited knowledge of the exact toxicity associated with each 
specific aggregate species. This heterogeneity dictates the need for determining the 
exact aggregation mechanism, defining structural elements related with the toxic forms 
of htt aggregates and highlights the intricacy of mutant htt toxicity. Debate continues 
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regarding the focal cause of toxicity associated with htt aggregates. Inclusion body 
formation, while the hallmark of HD,  may signify a protective cellular response to 
eliminate diffuse htt aggregates, which have been reported to be the acutely toxic.47 The 
monomeric form of htt-exon1 encompasses intrinsically disordered domains that interact 
intramolecularly to encourage toxic oligomerization of htt.49–51 Soluble oligomers can 
vary in stability and size, ranging from small dimers and tetramers to larger octamers 
and dodecamers. Htt has been known to form a variety of oligomers, as observed by 
AFM (atomic force microscopy), which can initiate htt fibril formation in vitro.34,44 
Oligomers morphologically and biochemically indistinguishable from those observed in 
vitro are detectable in transgenic cells expressing htt, HD mouse models, and patients’ 
brains.50,52  
Particular attention has been fixated on how flanking sequences on either side of 
the polyQ domain promote certain aggregation mechanisms. Addition of polyP residues 
to the C-terminus forces a PPII-like structure into the polyQ domain, which competes 
against the aggregation-prone β-sheet.53 Nt17 stimulates aggregation by encouraging 
formation of helical oligomers.26,53 The oligomer structure brings polyQ domains into 
closer proximity and lowers the energy barrier to nucleate β-sheet formation.53 This key 
role of Nt17 in the upstream stages of htt aggregation suggests that it is a viable 
therapeutic target.  
1.4 Structure and Functions of Nt17 
 Understanding the structural dynamics of Nt17 would provide a deeper 
understanding to the complexity of htt aggregation. Nt17 in ionic buffer is intrinsically 
disordered but demonstrates the ability to undergo conformational transitions leading to 
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an amphipathic α-helix (AH) when interacting with binding partners.20,30 The structure of 
an AH is favorable for establishing a collection of helix bundles in aqueous environment, 
driven by maximizing the interaction of the hydrophobic faces of adjacent helices.29,54 
The formation of these interacting helices has been anticipated to play a role in the 
preliminary stages of htt aggregation. Through ordering into helical bundles, Nt17 
promotes the stability of aggregates and an oligomeric intermediate aggregation 
pathway, leading to an increased rate of aggregation.55–57 Oligomers are a potentially 
critical toxic species; therefore, the promotion of oligomerization by Nt17 could have 
potentially important outcomes in htt-related toxicity. Intermolecular interactions leading 
to the self-association of Nt17 enables the formation of these helical oligomers, leading 
to β-sheet rich fibrils associated with the polyQ core; however, Nt17 maintains its AH 
structure in the fibril.26  
 Peptides containing polyQ but lack the N-terminal flanking sequence tend not to 
form oligomeric intermediates, thus proceeding directly to fibrillar aggregates.26,30 
However, pure polyQ-peptide aggregating on a surface have been discovered to form 
oligomers.33,54 Free Nt17, which lacks the polyQ domain, has been demonstrated to 
inhibit formation of Nt17Q37P10KK peptides in vitro.26,30 The mechanism appears to be 
identical to the mechanism by which nucleation occurs, by increasing the distance 
between adjacent polyQ tracts and the energy for polyQ fibrillization to occur.58 Steric 
hinderances can also interfere with the ability of Nt17 to promote oligomerization. In 
cases where a Myc-tag preceded Nt17 in full length exon1, the formation of oligomers in 
vitro was reduced without changing the rate of fibril formation when equated to similar 
proteins that lacked the Myc-tag.20 Increased structural complexation using small 
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molecules, antibody-antigen, or molecular chaperones that interacts directly with this 
domain are also practical means of inhibiting N-terminal aggregation.3,59–62  
Membrane binding AHs is a common motif in proteins and peptides, with Nt17 
demonstrating these functions.28 AH lipid binding begins with separation of the 
hydrophilic and hydrophobic sides of the AH structure. Hydrophilic residues are solvent 
exposed and accessible for multiple binding partners, while hydrophobic residues are 
buried in the acyl chain of the lipid membrane, leading to an AH structure parallel with 
the surface.28,63,64 This binding approach is driven by long-range electrostatic 
interactions between the peptide and lipid headgroups coupled with conformational 
rearrangements of the peptide that allow the hydrophobic residues to remain closer to 
the membrane core.64 
Supplementary AH abilities of Nt-17 function in the preliminary insertion of polyQ 
peptides into a lipid membrane structure, which can increase the local concentration of 
aggregation-prone polyQ region. This interaction strengthens the reactions between 
polyQ domains through a 2-dimensional diffusion on the membrane surface.54,65,66 AHs 
also have several practical features, including detection of defects induced by curvature, 
which allows preferential sensing and binding of highly curved membranes.67 Since AHs 
weakly bind membranes, their interactions can be effortlessly maintained. For example, 
Nt17 can isolate truncated htt-exon1 peptides to regions of curvature on supported lipid 
bilayers.68 Detailed understanding of Nt17 lipid binding mechanisms can elucidate the 
methods of htt aggregation at lipid surfaces. 
1.5 Post Translational Modifications within Nt17 
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 Within the Nt17 helix, there are several sites that undergo post-translational 
modifications (PTMs), with some sites associated with multiple PTMs.69–71 These PTMs 
include acetylation,72,73 oxidation,74 SUMOylation,69,75,76 ubiquitination,77 and 
phosphorylation.43,51,78–81 Other less known, but observed, PTMs include 
palmitoylation82 and transglutamination83. Collectively, these PTMs of Nt17 have 
significant effects on htt function and disease progression. Factors of htt function 
including translocation,84–86 membrane association and binding,76,81,87 toxicity,29,69,70,75,78 
and aggregation76,78,81,87 can be traced back to specific amino acids within Nt17. 
 
Figure 1.5: View of Nt17 helix with PTMs. The view down the top of the barrel of the Nt17 α-
helix shows hydrophobicity of each residue (as indicated by legend) and all reported PTMs. The 
center line represents the membrane of cells, in which all residues below the line are known to 
bury within the membrane due to their hydrophobic nature. Adapted in part with permission from 
Arndt, J.R. et al. The Emerging Role of the First 17 Amino Acids of Huntingtin in Huntington’s 
Disease. Copyright 2015 Biomolecular Concepts. 
 
 The localization of lysine residues on the edge of the hydrophilic portion of the 
AH (K6 and K15) suggests a potential roles in stabilizing early htt oligomers.88 Three 
lysine residues are found within Nt17, (K6, K9, K15) and all are available for acetylation, 
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SUMOylation, and ubiquitination. Acetylation of these residues decreases the severity of 
htt lipid binding, resulting membrane disruption, and promotes the formation of large 
globular aggregates instead of fibrils.87 Proteomic mapping via mass spectrometry 
confirmed K9 is significantly acetylated in mammalian cell lysates.72  
SUMOylation of these lysine residues modify htt-induced pathogenesis for both 
cell and animal models69,75 and alter aggregation and the ability of htt to bind 
membranes.69,76 At K6 and K9, SUMOylation stabilized htt-exon1 fragments, effectively 
retarding aggregation and toxicity in Drosophila models.69 SUMOylation by Rhes, a 
small G protein, specially binds mutant htt over wild type by acting as a SUMO E3 
ligase, increasing toxicity and soluble levels of htt.89 The natural ubiquitination process 
tags proteins for degradation and is known to compete for the same lysine residues as 
SUMOylation, and both reduce the toxicity of mutant htt.90 However, the presence of 
ubiquitin in htt inclusions demonstrate that this degradation mechanism becomes 
inefficient in HD.91 Since SUMOylation and ubiquitination compete for the same lysines, 
it can be implied that one method could be used to control the other. For example, 
serine 13 (S13) and serine 16 (S16) phosphomimics in htt were found to regulate 
SUMO-1 modifications in cells and in vivo.43,80 These same phosphomimics also 
enhance K6 htt SUMOylation, which could modulate K9 acetylation.75  
There are three phosphorylation sites within the Nt17 of htt-exon1, S13, S16 and 
threonine 3 (T3), with even more sites in full-length htt. Extensive studies suggest that 
htt phosphorylation is associated with reduced levels of mutant htt toxicity, aggregation, 
and lipid binding.43,71,78,80,81,92,93 Phosphorylation at S13 or S16 reduce helical 
content.81,92 whileT3 phosphorylation stabilizes helical content, yet phosphorylation at all 
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three sited reduced aggregation.94,95 A combination of serine phosphorylation mimics 
established that serine to aspartate mutations greatly reduced the stability of the fibril 
structure and formation htt aggregates.43,58 Htt with bonafide phosphorylation at S13 
and S16 aggregated similarly to htt-constructs containing phosphomimetic mutations at 
these same sites.43,80,92 Therefore, it is demonstrated that serine phosphomimetic 
mutations are effective mimics for probing the impact of htt phosphorylation on 
aggregation.  
1.6 Significance of Lipid Interactions with Huntingtin Protein 
In amyloid-based neurodegenerative diseases like HD, membrane perturbation 
and permeabilization is a commonly proposed toxic mechanism.26,96 Cellular membrane 
are predominately comprised of lipids, which are comprised of a hydrophilic head and 
hydrophobic tail. Lipids readily self-assemble to form bilayers in aqueous solution. Htt 
itself is highly associated with a variety of membranes within cells, and localization to 
these membranes is a prominent feature in many normal functions attributed to 
htt.55,87,91 Several membrane related functions in which the lipid-binding properties of 
Nt17 may play a role, include cholesterol and energy homeostasis,97 cellular 
adhesion,98 motility,99,100 and molecular scaffolding.101 Htt functions in the transport of 
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Figure 1.6: Mechanism of membrane binding interactions of htt. A key function of the AH of 
Nt17 is the ability to sense membranes. Nt17 is crucial for the mechanism of lipid membrane 
association of htt in that it forms two faces, hydrophobic and hydrophilic, in the presence of 
binding partners. These allow for self-association in early stages of aggregation, or the ability to 
preferentially bind to lipid membranes.  
 
Nt17 also facilitates the trafficking of htt-exon1 to membranes associated with 
membranous organelles including ER, mitochondria, Golgi and autophagic 
vacuoles.105,106 Membrane association is also important for htt localization to subcellular 
components, such as the nucleus and plasma membrane.101 The ability of the AH 
structural qualities of Nt17 to engage membrane curvature sensing demonstrates a 
mechanistic role in these cellular functions.29 Specifically, htt trafficking between the 
nucleus and cytoplasm occurs through Nt17-regulated reversible association with 
several membranous organelles.105  
With regard to toxicity, htt aggregates alter membrane structure and 
stability.45,48,105,107–109 Large unilamellar vesicles (LUV) that interact with htt-exon1 
fragments enhance fibril formation in vitro.96 Mitochondrial and vesicular trafficking are 
impaired in htt knock-out mice,110,111 Htt interacts with acidic phospholipids101 which 
could be instrumental in nucleating aggregation. Cumulative evidence suggests that a 
fundamental component of HD pathology is the consequence of toxic loss-of function, 
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theoretically due to the disturbance of interactions between membranes and 
htt.14,17,112,113 Htt knockout mice display amplified apoptosis and premature embryonic 
lethality,17,112 and mice that are heterozygous for the htt knockout show significant 
neuronal degeneration,17,18 signifying that htt is a necessary protein for normal function. 
Membranes may represent direct targets of toxic htt aggregates. Htt-exon1 disturbs the 
structural integrity of lipid bilayers in a polyQ-dependent manner.114,115 Many aggregate 
species are localized to damaged membranes within cells,14,96,116,117 such as fibrils 
distorting ER morphology and dynamics in HD,117 and membranous structures are 
incorporated into htt inclusions.116 Htt-exon1 oligomers bind to and disrupts membranes 
consisting of brain lipids, and these interactions were correlated to membrane leakiness 
and neuronal toxicity.96 
Altering the lipid composition of membranes plays an important role in htt 
aggregation.65  Lipid properties, including size, charge and degrees of saturation result 
in a broad array of physicochemical membrane features. Since physicochemical 
properties of a membrane system are governed by membrane composition,118 this 
explains why adjustments to membrane composition impact the interaction between htt 
and lipid surfaces. For example, the size of the lipid headgroup is key for developing the 
favored curvature of a bilayer system,119 while the size and saturation of the lipid tail 
impact features such as packing and fluidity.120 Amplified membrane fluidity results in a 
greater tendency for the occurrence of membrane defects,121 which ties into the defect 
detecting properties of the Nt17 domain.27 Structural analysis by solid state NMR 
demonstrates that Nt17 undergoes a structural transition from random-coil in solution to 
an α-helical structure upon binding lipid bilayers.28,101 In addition, htt monomers disrupt 
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the physical packing of POPC bilayers in a way that potentially favors intermolecular 
Nt17 association.63 PC/PS vesicles catalyze htt aggregation by promoting specific 
orientation within Nt17 on the membrane and increasing the local htt concentration on 
the surface.65 This effect is dependent on polyQ length and peptide to lipid ratios.122 
Comparatively, the presence of total brain lipid extract (TBLE) diminishes fibrillization of 
htt.66,123 This supports the notion that lipid composition is a factor in the effect of a 
membrane on htt aggregation.  
Nt17 plays an essential role in the ability of htt to bind membranes. While 
synthetic polyQ peptides lacking Nt17 did not appreciably interact with model lipid 
membranes, lipid membranes stabilized discrete oligomers of a Nt17Q35 peptide, and a 
Nt17Q35P10 peptide formed a variety of htt aggregates that readily damaged bilayers.26 
Computational studies further back the vital role of Nt17 in htt/lipid interactions and 
deliver evidence that the presence of both Nt17 and polyP flanking regions enhance the 
interaction of htt with bilayers.124 The supportive effect of Nt17 and the polyP domain in 
disrupting membranes may be principally significant considering interactions between 
these two domains in a cellular environment are altered when the polyQ domain is 
expanded beyond the threshold associated with HD.125 Induced mechanical changes in 
the membrane due to the buildup of monomeric htt and prefibrillar aggregates engaging 
directly on the surface disrupt bilayer integrity and could serve a role in htt-related toxic 
mechanisms.115,126  As the previously discussed PTMs are known to be involved in htt 
translocating to specific organelles105,127 and should be considered in regulating the 
interaction of htt with lipid membranes mediated by Nt17, they likely also impact the 
aggregation of htt in the presence of lipid membranes.   
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1.7 Dissertation Rationale 
Due to the importance of Nt17 in the interactions with membranous organelles 
and regulating aggregation, the roles that these interactions potentially play in HD 
pathology are crucial, yet unknown. Surfaces, particularly lipid surfaces associated with 
membranous organelles, have influences related with their interfaces. Such influences 
include electrostatic interactions, and the electrostatics between surfaces and htt have a 
huge role.  
In Chapter 2, we explored combinations of changing the membrane electrostatics 
and changing the Nt17 electrostatics by mimicking a known post translational 
modification (PTM). Certain PTMs within Nt17 are known to modify HD pathology, and 
due to Nt17’s inclination to interact with lipid membranes, the influence of these 
mutations were explored with various model lipid membranes. Specifically, 
phosphorylation at T3, S13, and/or S16 improves phenotype and delays fibrilization in 
HD models. The impact of introducing phosphomimetic mutations (T3D, S13D and 
S16D) into htt-exon1 changed htt’s interaction with and aggregation in the presence of 
lipids, reliant on the lipid system. Lipid systems included total brain lipid extract (TBLE), 
POPC and POPG, and were chosen to mimic a complex neutral lipid system, a neutral 
zwitterionic model lipid system, and a negatively charged lipid system.  
Given that aggregation happens in a much more complicated environment, 
specifically in the highly crowded cytosol, the effects of macromolecular crowders 
present in the cytosol were examined with htt. In Chapter 3, changes were explored in 
the interfaces of membranes through the addition of various macromolecular crowders 
Dextran, Ficoll and PEG, with htt. This poses the question, if we crowd the liquid 
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surface, i.e. the liquid portion of the solid/liquid interface, how does that impact the 
interactions at surfaces? The differences of crowding interactions with htt in a 
solid/liquid interface, represented by in situ experiments on mica, were compared to 
crowding a gel-like/liquid interface represented by in situ experiments on TBLE bilayers.  
In addition, we adapted many of these assays and experiments used in the 
laboratory into new, upper level, undergraduate biochemistry laboratory experiments for 
students presented in an appendix. In short, over a six-week time span, students are 
immersed in a graduate level setting and perform an experiment with minimal guidance 
from prep work to completion. Students are asked to present their findings in a 
conference setting, with the final report written in the ACS journal Biochemistry format. 
Moving away from the traditional “cookbook” format of undergraduate laboratories, this 
experiment was well received as an addition to the undergraduate biochemistry 
curriculum.  
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2. Phosphomimetic Mutations Impact Huntingtin Aggregation in the 
Presence of a Variety of Lipid Systems 
 
ABSTRACT 
Huntington’s Disease (HD) is a neurodegenerative disorder caused by the abnormal 
expansion of a polyglutamine (polyQ) tract in the first exon of the htt protein (htt). PolyQ 
expansion triggers the aggregation of htt into a variety of structures, including oligomers 
and fibrils. This aggregation is impacted by the first 17 N-terminal amino acids (Nt17) of 
htt that directly precedes the polyQ domain. Beyond impacting aggregation, Nt17 
associates with lipid membranes by forming an amphipathic α-helix. Post-translational 
modifications within Nt17 are known to modify HD pathology, and in particular, 
phosphorylation at T3, S13, and/or S16 retard fibrilization and ameliorates phenotype in 
HD models. Due to Nt17’s propensity to interact with lipid membranes, the impact of 
introducing phosphomimetic mutations (T3D, S13D and S16D) into htt-exon1 on 
aggregation in the presence of a variety of model lipid membranes (total brain lipid 
extract, POPC, and POPG) was investigated. Phosphomimetic mutations altered htt’s 
interaction with and aggregation in the presence of lipids; however, this was dependent 
on the lipid system.  
2.1 Introduction 
A prominent feature of many neurodegenerative diseases, e.g. Alzheimer’s 
disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD), is the 
deposition of proteinaceous material in the form of plaques and inclusions within tissues 
and cellular compartments. These depositions are predominately comprised of amyloid 
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that are defined by a fibrillar morphology and a cross β-sheet structure. In particular, HD 
is an autosomal dominant genetic disorder caused by the expansion of a polyglutamine 
(polyQ) region in the first exon of the huntingtin protein (htt) above a critical threshold 
(~35 repeat glutamine residues),1 and this expansion promotes htt’s aggregation into 
fibrils.2 Htt aggregation is a multifaceted process involving, beyond fibrils, a variety of 
other aggregate species, including oligomers, annular structures, and amorphous 
aggregates.2–4 Due to the heterogeneous nature of htt aggregation, debate continues 
about the role different aggregate species play in toxicity. In this regard, htt oligomers,5–
7 fibrils,8,9 and inclusions10 have all been directly implicated as toxic entities.  
Within the cellular environment, htt associates with a variety of membranous 
surfaces, e.g. mitochondria, endoplasmic reticulum (ER), the nuclear envelope, 
tubulovesicles, endosomes, lysosomes, and synaptic vesicles.11–16 These membranes, 
predominately comprised of lipids, provide subcellular environments that influence htt 
aggregation.17 In mouse models of HD, lipids accumulate in htt aggregates and 
inclusions,18–20 and htt aggregates disrupt lipid membranes21–24 and organelle 
integrity.10,15,16,25 Htt’s interaction with membranous surfaces not only influences 
aggregation but may also be involved directly in toxic pathways. Several model lipid 
membranes influence htt aggregation in vitro in a variety of ways.22,23,26–31 POPC/POPS 
lipid vesicles accelerate fibril formation by promoting a distinct aggregation pathway;32 
however total brain lipid extract suppresses fibrilization.21,33  
The first 17 N-terminal amino acids of htt (Nt17) that directly precede the polyQ 
region is implicated in both htt aggregation and interaction with lipid membranes.21,34 
Nt17 is predominately disordered in solution but has a propensity to adopt an 
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amphipathic α-helical structure upon interaction with a binding partner. Nt17 domains of 
several htt proteins can associate to form α-helical rich oligomers.35,36 These oligomers 
enhance fibril formation by bringing together polyQ domains of different htt proteins.35,36 
Beyond this role in promoting aggregation, the ability to form an amphipathic α-helix 
facilitate the binding of htt-exon1 to lipid membranes. A variety of post-translational 
modifications (PTMs) occur within Nt17, with implication for htt aggregation and 
membrane interactions. These PTMs include phosphorylation,37–40 oxidation,41,42 
acetylation,30,43 SUMOylation,32–35 and ubiquitination.32–34 PTMs impact htt function, 
translocation, and toxicity.37,44–46 In particular, Nt17 contains three phosphorylatable 
residues: threonine 3 (T3), serine 13 (S13), and serine 16 (S16). Phosphorylation of 
S13 and S16 reduces accumulation of htt and pathogenesis in animal models, modifies 
htt subcellular localization, reduces aggregate stability, and inhibits fibril 
formation.37,39,47–51 Imitating threonine 3 (T3) phosphorylation enriches polyQ-mediated 
toxicity in Drosophila models of HD but increases the amount of insoluble htt-exon1 
species.37,51 More recent literature on htt-exon1 peptides demonstrate that inducing 
phosphorylation50–53 or adding a negative charge51,54 through aspartic acid single point 
mutations to the T3 residue leads to a decrease in fibril elongation.51,55 Inhibition of 
fibrilization via phosphorylation also appears related to modifications in the nucleation 
process related to the formation of α-helical rich oligomers facilitated by Nt17.47 
 Here, the aim was to determine how phosphorylation at T3, S13, and S16 
influence the ability of htt-exon1 to directly interact with lipid membranes and how these 
interactions influence htt aggregation. To achieve this, aggregation of htt-exon1 proteins 
containing phosphomimetic mutations (T3D, S13D, or S16D) in the presence and 
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absence of lipid membranes was investigated by various biophysical techniques. Lipid 
systems investigated were TBLE, POPC, and POPG. Phosphorylation altered htt’s 
interaction with and aggregation in the presence of lipids, but this was heavily 
influenced by the specific lipid systems exposed to htt. 
2.2 Materials and Methods 
2.2.1 Preparation of Phosphomimetic Constructs. Extracted DNA from a glutathione 
S-transferase (GST)-htt-exon1(46Q) fusion protein was inserted at cleaved sites 
BamH1 and Sal1 vectors within a pGEX-5X-1 plasmid. This region was replaced with 
three separate constructs, in which an aspartic acid residue replaced the three-
phosphorylation post translational modification sites within the Nt17 domain (T3D, S13D 
and S16D). The construct plasmids were transformed into One Shot thermocompetent 
STBL3 E. Coli cells and made into glycerol stocks stored at -80°C for future purification 
in the same manner as the unmodified wild-type (WT). 
2.2.2 Expression, Purification of (GST)-htt-exon1 Fusion Protein. (GST)-htt-
exon1(46Q) fusion proteins (WT, T3D, S13D and S16D) were purified as described 
previously.56 In short, GST-htt-exon1 was expressed with isopropyl B-D-thiogalactoside 
for 4 hours at 30°C in E. Coli. Cells were lysed with lysozyme (0.5 mg/mL) and 
sonication, and fusion proteins were purified using a 5 mL GST affinity column and 
liquid chromatography (LPLC, Bio Rad). Relevant protein bands were observed with gel 
electrophoresis technique and Coomassie blue staining to assess purity and 
appropriate fractions. Protein concentration was determined using Coomassie Bradford 
reagent.  Before each experiment, pre-existing aggregates were removed through high 
speed centrifugation at 20,000g for 30 minutes at 4°C. Initiation of aggregation through 
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cleavage of the GST tag is performed by the addition of Factor Xa protease (New 
England Bio Labs). All experiments were performed in buffer A (50mM Tris-HCl, pH 7, 
150mM NaCl). 
2.2.3 Lipid Preparation. Total brain lipid extract (TBLE), 1-Palmitoyl-2-oleoyl-glycero-3-
phosphatidylcholine (POPC), and 1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-
glycerol (POPG) were purchased as lyophilized powders (Avanti Polar Lipids). Lipids 
were dissolved in chloroform and aliquoted for further use. Residual traces of solvent 
were evaporated overnight in high vacuum. Resulting lipid films were hydrated in buffer 
A at 60°C with vortex mixing until all lipid was suspended in solution. Vesicle formation 
was promoted by 10 freeze/thaw cycles using liquid N2 followed by bath sonication at 
room temperature for 1 hour. 
2.2.4 Thioflavin T (ThT) Aggregation Assay. Htt-exon1(46Q) constructs were diluted 
to a final concentration of 20 µM in the presence of 125 µM ThT (Sigma-Aldrich, St. 
Louis, MO) and the desired lipid vesicles if needed. In experiments with vesicles, a 10:1 
lipid:protein ratio was used, resulting in a lipid concentration of 200 µM. Assays were 
performed in black Costar 96-well plates with clear flat bottoms (100 µL per well), and 
ThT fluorescence was monitored with a microplate reader (SpectraMax M2). 
Experiments were run at 37°C with readings every 5 minutes for 18 hours at 440 nm 
excitation and 484 nm emission. For an individual experiment, all conditions were run in 
triplicate, and a minimum of three independent experiments were performed. 
2.2.5 Polydiacetylene (PDA) Vesicle Binding Assay. 10,12-tricosadiynoic acid (GFS 
Chemicals, Columbus, OH) and lipid system of choice were dissolved at a 2:3 molar 
ratio in a solution of 1:4 ethanol/chloroform. Solution was evaporated off under a gentle 
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stream of N2, and the film was dissolved with buffer A at 70°C. The solution was 
sonicated for 10-minute intervals at 100 W using a sonic dismembrator (FisherSci) until 
solution was sufficiently opaque and stored at 4°C overnight to ensure self-assembly of 
the mixture into vesicles. Polymerization of the PDA was initiated by irradiation at 254 
nm for 10 minutes at room temperature with stirring, resulting in a blue, opaque solution. 
The colorimetric response was monitored by UV-Vis spectroscopy to quantify protein 
binding to vesicles with a SpectraMax M2 microplate reader (Molecular Devices). The 
assay was performed in a 96-well plate format (100 µL total volume per well), and each 
condition was performed in triplicate per experiment. A minimum of three unique 
experiments were performed. Each plate contained negative controls (neat buffer A) 
and a positive control (final concentration of 100 µM NaOH). The NaOH control was 
used to standardize PDA results across experiments.57 The percent colorimetric 
response (% CR) was determined every 5 min for 18 hours at 37°C by measuring the 
blue absorbance (640 nm, Ablue) and the red absorbance (500 nm, Ared) using the 
following equation:  
(𝐸𝐸𝐸𝐸𝐸𝐸. 2.1)         % 𝐶𝐶𝐶𝐶 = �
𝑃𝑃𝐵𝐵0 − 𝑃𝑃𝐵𝐵1
𝑃𝑃𝐵𝐵0
� ∗ 100 
PB is defined as Ablue/(Ablue+Ared). PB0 is determined from the negative control, and  PB1 
is obtained is obtained from each experimental condition.58,59 
2.2.6 Atomic Force Microscopy (AFM). For ex situ AFM experiments, htt-exon1(46Q) 
(20 µM) was incubated in the absence or presence of lipid vesicles (10:1 lipid to protein 
ratio) at 37°C and 1400 rpm in an orbital thermomixer. At designated time points, 2 μL 
aliquots of each sample were deposited onto freshly cleaved mica (Ted Pella Inc., 
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Redding, CA) for 1 minute, washed with 200 μL of 18 MΩ ultrapure water, and dried 
under a gentle stream of filtered air. Samples were imaged using a Nanoscope V Multi-
Mode scanning probe microscope (VEECO) equipped with a closed loop vertical 
engage J-scanner. Silicon-oxide cantilevers with a nominal spring constant of 40 N/m 
and a resonance frequency of ~300 kHz were used. Scan rate was set at 1.99 Hz with 
cantilever drive frequencies at 10% below resonance. For in situ AFM experiments a 
tapping mode fluid cell with an O ring was equipped with a cantilever a nominal spring 
constant of 0.1 N/m. To prepare the TBLE bilayer, lyophilized lipid film was reconstituted 
in 25 mM Tris buffer at 1 mg/mL. The resulting TBLE solution underwent ten freeze-
thaw cycles followed by 10 min of bath sonication. The resulting TBLE vesicles were 
directly injected into the fluid cell (30 µL), and the formation of a supported lipid bilayer 
was monitored via continuous AFM imaging.  Once a continuous 40 µm x 40 µm patch 
of supported lipid bilayer formed, htt constructs that had been incubated on ice with 
factor Xa for 2 h was injected into the fluid cell to a final concentration of 10 µM. The 
lipid bilayer exposed to htt was continuously imaged. Resulting images from both ex situ 
and in situ were then analyzed using the MATLAB image processing toolboxes 
(MathWorks) as described.60,61 
2.3 Results 
2.3.1 Phosphomimetic mutations in Nt17 alter htt aggregation. All experiments 
presented here used GST-htt-exon1 fusion proteins with 46 repeat glutamines (htt-
exon1(46Q)). Single amino acids within Nt17 (T2, S13, or S16) were mutated to aspartic 
acid to mimic phosphorylation. For convenience, the control htt-exon1(46Q) protein 
without mutations will be referred to as httNT, and the htt-exon1(46Q) protein with 
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phosphomimetic mutations will be referred to as httT3D, httS13D, and httS16D respectively. 
For all GST-htt fusion proteins, cleavage of the GST tag with Factor Xa initiates 
aggregation. While phosphomimetic mutations in Nt17 are known to slow 
fibrillization,39,47 the ability of the specific experimental system used here to recapitulate 
this feature needed to be verified. Fibril formation of each htt protein was monitored with 
a ThT assay (20 µM concentration, Fig. 1), and all three mutations reduced aggregation 
over a 9 h period. HttT3D impeded fibril formation to the greatest extent (a 75% reduction 
compared to httNT in the maximum ThT signal observed), followed by httS16D (61 % 
reduction). Of the three mutations, S13D had the mildest impact on fibril formation, 
reducing the maximum ThT signal by only 26%.  
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Figure 2.1: The impact of phosphomimetic mutations on htt aggregation. (A) Aggregation 
of httNT, httT3D, httS13D, and httS16D tracked by a ThT assay. (B) Quantification of the maximum 
ThT fluorescent signal observed. Error bars represent SEM. * corresponds to p<0.01 and ** 
corresponds to p<0.05 when compared with httNT. (C) Representative ex situ AFM images of 
aggregates formed at various time points from 20 µM incubations of httNT, httT3D, httS13D, and 
httS16D. (D) Histograms of the average height along the contour of fibrils of httNT, httT3D, httS13D, 
and httS16D measured from AFM images. (E) Morphological correlation plots (height vs diameter) 
of individual oligomers observed in AFM images at 3 and 8 h for all four htt constructs. In 
addition, normalized height (top) and diameter (right) histograms are also presented. 
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 To further characterize the impact of phosphomimetic mutations on htt 
aggregation, AFM analysis was performed (Fig. 1C). HttNT, httT3D, httS13D, and httS16D 
were incubated (20 µM, 37°C), sampled at 1, 3, 5, and 8 h, and imaged by AFM. For 
httNT, a few short fibrils were observed after 1 h of incubation, and these fibrils grew in 
number and length with time. After 8 h, an extensive number of httNT fibrils were 
observed. With each phosphomimetic mutation, fewer fibrils were observed compared 
with httNT, and consistent with the ThT assay, httS13D had the smallest impact on 
fibrillization. The length of fibrils observed from htt constructs containing 
phosphomimetic mutations tended to be shorter compared to httNT due to the reduced 
rate of fibril formation. However, previous ssNMR studies demonstrates that 
phosphomimetic mutations in Nt17 do not significantly alter the underlying htt fibril 
structure.47 That is, the polyQ core was unchanged even though the rate of formation 
and aggregate stability is altered. To assess if fibrils formed from the four htt constructs 
used here may have similar underlying structure, the average height along the contour 
of all fibrils observed in AFM images was determined and used to construct histograms 
(Fig. 1D). This measurement was chosen as even though the length of fibrils may be 
different, if the underlying structure is similar the thickness (measured as height along 
the contour) would be the same, and differences in the average height along the 
contour of amyloid fibrils are associated with polymorphic fibril structures associated 
with other amyloid proteins.62 Fibrils of all four constructs had similar average heights 
(mode of ~7 nm). The average height along fibril contours observed here is consistent 
with the phosphomimetic mutations not altering the underlying fibril core structure.  
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 Beyond fibrils, htt aggregates into a heterogenous mixture of oligomers. To 
determine if phosphomimetic mutations in Nt17 altered oligomer morphology, the height 
and diameter of oligomers was measured after 3 and 8 h of incubation using automated 
scripts in MATLAB. For this analysis, oligomers were defined as any feature more than 
0.8 nm in height with an aspect ratio (longest distance across to shortest distance 
across) <3.0, indicating a globular structure. Correlation plots of diameter vs height, as 
well as histograms for each dimension, were constructed (Fig. 1E). HttNT formed a 
heterogeneous mixture of oligomers, which is particularly pronounced in the height 
histograms. While httNT oligomers were diverse in morphology, the mode height was 5-
7nm at 3 h with a slight shift to larger oligomers at 8 h. For example, there was a 
sizeable population of httNT oligomers larger than 10 nm in height after 8 h. Oligomers 
formed from phosphomimetic htt constructs displayed less heterogeneity. In general, 
oligomers formed from htt containing phosphomimetic mutations tended to be smaller, 
which may be consistent with previous reports that Ser-to-Asp mutations in htt reduce 
its ability to form α-helix rich oligomers.47 HttT3D formed oligomers with a mode height of 
2.5-3.5 nm at 3 h. There was an abrupt shift to larger oligomer species (mode height of 
6-8nm); however, only a few httT3D oligomers grew beyond 10 nm in height. Both httS13D 
and httS16D formed smaller oligomers than httNT at 3 h (mode heights of 2.5-4 nm and 
2.5-6 nm respectively). While httS13D displayed a small shift in oligomer height at 8 h 
(mode height of 4-6 nm), the predominant morphological changes associated with 
httS13D and httS16D at 8 h was a broadening of oligomers that manifested as a slight shift 
(development of a tail) in the diameter histograms. Collectively, these observations 
suggest that phosphomimetic mutations impact htt aggregation at the oligomeric stage. 
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As α-helical rich oligomers mediated by Nt17 are implicated in mechanisms to nucleate 
fibrillization,35,36 reduction in fibril formation associated with phosphorylation may be due 
to differences in efficiency of formation and types of oligomers formed. 
2.3.2 Phosphomimetics of htt alter aggregation in the presence of lipids. Having 
established an experimental system, investigations aimed at elucidating the role of 
phosphorylation on htt/lipid interactions were performed. For these studies, three lipid 
systems were chosen as lipid composition can heavily influence amyloid formation. The 
first lipid system was total brain lipid extract (TBLE). TBLE has been shown to alter htt 
aggregation by suppressing fibril formation21,33 and consists of a physiologically relevant 
mixture of lipid components. In addition, two simpler lipid systems were investigated 
(POPC and POPG). With the phosphomimetic constructs neutralizing the net positive 
charge of Nt17, these two simplified systems were chosen because they have the same 
tails but differently charged head groups, as POPC is zwitterionic and POPG is anionic. 
 To assess the impact of the three lipid systems on fibrillization of the four htt 
constructs, ThT assays were performed in the presence of lipid vesicles (Fig. 2). For 
these assays, the lipid to htt molar ratio was 20:1, and all vesicles were in the range of 
140-180 nm in diameter as assessed by dynamic light scattering. Consistent with 
previous reports,21,33 TBLE reduced httNT fibrillization relative to the absence of lipid 
(compare the maximum ThT signals in Figure 2A to Figure 1B). This reduction in 
fibrillization associated with the presence of TBLE vesicles was also apparent for the 
three phosphomimetic htt constructs. Relative to httNT in the presence of TBLE, the 
phosphomimetic mutations further reduced fibrillization with the same pattern as 
observed in the absence of lipids. That is, httT3D produced the smallest ThT signal (77% 
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reduction compared to httNT in the presence of TBLE), followed by httS16D (54% 
reduction), and httS13D (29% reduction). 
 
Figure 2.2. Phosphomimetic mutations influence htt aggregation in the presence of lipid 
vesicles. ThT assays and quantification of the maximum ThT fluorescent signal observed for 
httNT, httT3D, httS13D, and httS16D. Error bars represent SEM in the presence of vesicles comprised 
of (A) TBLE, (B) POPC, and (C) POPG. * corresponds to p<0.01 and ** corresponds to p<0.05 
when compared with httNT. 
 
 With the addition of POPC or POPG vesicles, httNT fibrillization was enhanced 
compared with aggregation reactions in the absence of lipids (compare Figure 2B-C 
with Figure 1B), with POPG having a significantly larger effect. The fibrillization of the 
phosphomimetic htt constructs was also enhanced in the presence of POPC or POPG, 
and the extent of fibrillization continued to follow the same pattern. That is, httT3D 
aggregated the least, followed by httS16D and httS13D respectively. However, the relative 
inhibition of fibrillization with respect to httNT aggregation in the presence of POPC or 
POPG was reduced. With POPC, there was no significant difference between the ThT 
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signal produced by httNT and httS13D. With POPG, the ThT signal was not significantly 
different between httNT and httS16D. Furthermore, there was a significant increase in ThT 
signal in httS13D compared to httNT in the presence of POPG. 
 To further establish the impact of the three lipid systems on the aggregation of 
the htt constructs, AFM analysis was performed. As before, incubation experiments 
were performed with fresh preparations (20 µM) of httNT, httT3D, httS13D, and httS16D, but 
this time they were incubated with vesicles of TBLE, POPC, or POPG (20:1 lipid to 
peptide ratio). Background images of these lipid systems deposited on mica without htt 
are shown in Figure 3. These incubations were sampled at 1, 3, 5, and 8 h.  
 
Figure 2.3. Representative AFM images of backgrounds associated with deposited 
solutions of lipid vesicles. Clean mica and mica exposed to TBLE, POPC, or POPG vesicles 
are compared. The green line in each image corresponds to the height profile shown directly 
below each image. 
 
Representative AFM images of aliquots removed from these solutions after 8 h of 
incubation are shown in Figure 4. Representative AFM images of the other three time 
points for incubations with TBLE, POPC, or POPG vesicles are shown as Figures 5, 6, 
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and 7 respectively. A variety of aggregates (oligomers and fibrils) are observed on mica 
under all conditions. The average height along the contour of fibrils was measured to 
determine if the presence of the lipids altered fibril structure (Fig. 4B). Despite different 
rates of formation, there were not any significant differences in fibril structures across 
the four htt constructs within a single lipid system. However, the fibril structure appeared 
altered by POPG. With TBLE and POPC, the average height along the contour of the 
fibril was ~6-7 nm, which is consistent with fibrils formed in the absence of lipids. With 
POPG, the average height along the contour ranged from 3-5 nm, suggesting that the 
structure of fibrils formed in the presence of POPG may vary from fibrils formed in the 
absence of lipid. 
 
Figure 2.4. Phosphomimetic htt constructs form a variety of aggregates in the presence 
of lipid vesicles. (A) Representative ex situ AFM images of aggregates formed after 8 h of 
incubation (for other time points see figures S2-S4) from 20 µM incubations of httNT, httT3D, 
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httS13D, and httS16D in the presence of vesicles comprised of TBLE, POPC, or POPG. (B) 
Histograms of the average height along the contour of fibrils of httNT, httT3D, httS13D, and httS16D 
formed in the presence of vesicles comprised of TBLE, POPC, or POPG measured from AFM 
images.  
 
Figure 2.5. Phosphomimetic construct aggregates observed with ex situ AFM in the 
presence of TBLE. Representative ex situ AFM images of aggregates formed after 1, 3, and 5 
h of incubation from 20 µM incubations of httNT, httT3D, httS13D, and httS16D in the presence 
of TBLE. 
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Figure 2.6. Phosphomimetic construct aggregates observed with ex situ AFM in the 
presence of POPC. Representative ex situ AFM images of aggregates formed after 1, 3, and 5 
h of incubation from 20 µM incubations of httNT, httT3D, httS13D, and httS16D in the presence of 
POPC. 
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Figure 2.7. Phosphomimetic construct aggregates observed with ex situ AFM in the 
presence of POPG. Representative ex situ AFM images of aggregates formed after 1, 3, and 5 
h of incubation from 20 µM incubations of httNT, httT3D, httS13D, and httS16D in the presence of 
POPG. 
 Using the same criteria as before, the height and diameters of oligomers 
observed at 3 and 8 h of incubation were determined and used to build correlation plots 
and histograms (Fig. 8). The presence of all three lipid systems reduced the 
heterogeneity of httNT oligomers at a given time point. With TBLE, httNT oligomers were 
less heterogeneous than in the absence of lipids, displaying mode heights of 5-7.5 nm 
at 3 and 8 h. Phosphomimetic mutations promoted smaller oligomers than httNT in the 
presence of TBLE, with mode heights of 2-3.5 nm, 2-3 nm, and 2-6 nm for httT3D, httS13D, 
and httS16D respectively. After 8 h, the height distribution of oligomers formed from all 
phosphomimetic mutations shifted to larger size with increased heterogeneity. After 3 h 
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of incubation, POPC vesicles promoted small oligomers with all four htt constructs 
(mode heights of 2.5-4 nm, 2-3.5 nm, 2-3 nm, and 2-3 nm for httNT, httT3D, httS13D, and 
httS16D respectively). While oligomers formed from httNT and httT3D in the presence of 
POPC remained relatively small, oligomer formed from httS13D and httS16D were 
significantly larger at 8 h (mode heights of ~6-8 nm for both).  POPG initially promoted 
smaller oligomers with all four htt constructs (mode heights in the 2-4 nm range at 3 h); 
however, a population of larger oligomers appeared with POPG after 8 h for all four 
constructs, resulting in a more heterogeneous population. This shift was the most 
pronounced with httS16D.  
 
Figure 2.8. Lipids promote unique htt and phosphomimetic htt oligomer morphologies. 
Morphological correlation plots (height vs diameter) of individual oligomers observed in AFM 
images at 3 and 8 h for all four htt constructs in the presence of vesicles comprised of (A) TBLE, 
(B) POPC, and (C) POPG. In addition, normalized height (top) and diameter (right) histograms 
are also presented. 
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2.3.3 Phosphomimetics of htt impact binding in a lipid specific manner. As the 
presence of lipid vesicles altered htt aggregation (with and without phosphomimetic 
mutations) in a lipid specific manner, a series of colorimetric membrane binding assays 
using lipid/polydiacetylene (PDA) vesicles were performed to determine the impact of 
phosphomimetic mutations on membrane binding. These vesicles were made with 
either TBLE, POPC, or POPG as the lipid component. Lipid/PDA vesicles have varied 
colorimetric responses (CRs) when exposed to proteins or small molecules depending 
on the extent of interaction.58,59 The CR in the lipid/PDA vesicles is related to transitions 
of the PDA polymer backbone structure, which is affected by changes in tension 
associated with exogenous molecules interacting with and/or inserting into the vesicle.59 
By measurement of the absorbance of both the blue (640 nm) and red (500 nm) 
wavelengths of lipid/PDA vesicles upon exposure to htt-exon1(46Q), the percent CR 
was obtained, which directly corresponds to the protein–lipid interaction. In addition, 
these assays were normalized to an NaOH control, allowing for comparison across lipid 
systems.57  
Phosphomimetic mutations significantly enhanced the interaction of htt with 
TBLE as shown in Figure 9, with httT3D and httS13D having the strongest interaction with 
the membrane (~2x the maximum % CR compared to httNT, p<0.01). With TBLE, the 
enhanced interaction of httS16D compared to httNT was less pronounced and not 
statistically significant. In contrast, phosphomimetic mutations delayed the interaction 
between htt and POPC for the first 3.5 h. The αβα displayed by PDA/POPC vesicles 
exposed to httNT reached 9-10% within 1 to 2 h at which time the %CR leveled off to a 
relative steady state (max %CR of 13.1%). For all three phosphomimetic htt constructs 
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it took ~7-9 h to reach a similar %CR with POPC. After the 9 h experiments, only httS16D 
displayed a significantly smaller maximum %CR (10.7%, p<0.05) compared with httNT. 
Within the time frame of these experiments httNT and httS16D invoked a larger %CR with 
POPC vesicles compared with TBLE. Both httT3D and httS13D more strongly interacted 
with TBLE compared to POPC. As all three phosphomimetic htt constructs had similar 
interactions with POPC, these cross-system differences may be due to the complexity 
of lipid composition of TBLE. The interaction of htt with POPG was the weakest of the 
three lipid systems, and there did not appear to be any significant differences 
associated with httNT and the phosphomimetic htt constructs. 
 
Figure 2.9. Phosphomimetic mutations in htt alter its ability to bind a variety of lipid 
vesicles. Normalized PDA/lipid binding assays and the maximum relative %CR associated with 
exposure of PDA vesicles with the lipid component comprised of (A) TBLE, (B) POPC, or (C) 
POPG exposed to the four htt constructs. Error bars represent SEM. * corresponds to p<0.01 
and ** corresponds to p<0.05 when compared with httNT. 
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2.3.4 Phosphomimetics of htt influence disruption of lipid bilayers. While the three 
lipid systems impacted htt aggregation as demonstrated by ThT and ex situ AFM 
assays, both techniques monitor bulk aggregation within an incubation. That is, they do 
not distinguish between htt aggregation occurring on a membrane surface or in bulk 
solution. In addition, there did not appear to be a direct correlation between the extent of 
htt/lipid interaction as measured by PDA and fibrillization associated with the 
phosphomimetic htt constructs. As htt aggregation occurs via a unique mechanism on 
POPC/POPS lipid surfaces,32 it was hypothesized that phosphomimetic mutations may 
be impacting aggregation at membrane surfaces in a distinct manner that is masked by 
the bulk aggregation assay already employed. As a result, in situ AFM was employed to 
directly observe aggregation of the four htt constructs directly on lipid membranes.  
For these assays it is important to obtain stable, supported lipid membranes that 
are free of nanoscale defects. Unfortunately, such supported membranes were not 
reproducibly produced for the pure POPC or POPG systems. Supported TBLE bilayers 
were easily produced and were systematically exposed to the four htt constructs (final 
htt concentration of 10 µM in the fluid cell). Upon injection of htt, TBLE bilayers were 
continuously imaged to directly observe changes in morphology and the development of 
htt aggregates (Figure 10). Such supported bilayers of TBLE have been extensively 
used to investigate their interaction with amyloid-forming proteins via in situ AFM.62–66 
Across trials, the total concentration of lipid in the AFM fluid cell was maintained; 
however, observations were restrained to a 30 × 30 μm patch of supported bilayer that 
was verified to be defect-free (at the level of resolution of the AFM) prior to exposure to 
any htt constructs. Prior to exposure to htt, TBLE bilayers had a smooth morphology 
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(RMS roughness ~ 0.2-0.4 nm) and can be continuously imaged by AFM for at least 24 
h without inducing any morphological changes. 
 
Figure 2.10. Phosphomimetic mutations alter htt aggregation on the surface of a TBLE 
bilayer. (A) In situ AFM images of the same region of supported TBLE bilayers exposed to 10 
µM httNT, httT3D, httS13D, or httS16D as a function of time. Black arrows indicate the same region in 
consecutive images. Quantification of (B) the RMS roughness of regions of altered morphology 
and (C) the % area disrupted of supported TBLE bilayers exposed to phosphomimetic htt 
constructs as a function of time. Error bars represent SEM. 
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 Supported TBLE bilayers were systematically exposed to httNT, httT3D, httS13D, or 
httS16D at a final htt concentration within the fluid cell of 10 μM. Protein aggregation on 
the bilayer was directly monitored by continuous in situ AFM imaging for 3 h (Fig. 10). 
To quantify the extent of morphological changes on TBLE bilayers associated with 
exposure to htt constructs, the RMS roughness of the altered areas on the bilayer was 
determined and the % area of the bilayer displaying altered morphology (Fig. 10B-C).  
Upon initial exposure of the TBLE bilayer to httNT, discrete patches displaying a 
roughened morphology developed on the TBLE bilayer. These patches often contained 
features reminiscent of htt oligomers; however, fibrillar morphology was rarely observed. 
With time, the area of the bilayer altered by exposure to httNT increased (16±4% after 
0.5 h of exposure to 36±7% after 3 h). The roughness associated with these altered 
regions doubled within the same time frame (1.4±0.6 nm at 0.5 h to 2.8±1.0 nm after 3 
h). In comparison, httT3D deposited more aggressively on the TBLE bilayer, significantly 
altering its morphology. Initially, httT3D appeared to form patches that resembled densely 
packed small fibrils. However, with time these patches became granular in appearance 
(RMS roughness of 6.5±1.3 nm by 3 h) and dominated the image, covering 65±2% of 
the surface. HttS13D initially appeared as discrete fibrillar aggregates on TBLE bilayers. 
HttS13D did not develop the granular morphology observed with httT3D; rather, large 
regions of altered morphology protruding above the unperturbed bilayer regions 
developed. These regions were relatively smooth in appearance, but because they 
protruded so far above the unperturbed bilayer, had the largest observed RMS 
roughness (8.8±0.8 nm) after 3 h of exposure to httS13D and covered 61±1% of the 
surface.  Exposure to httS16D also resulted in regions of altered morphology on the 
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bilayer surface, but these regions often had fibril-like features extending from their 
periphery. The RMS roughness (5.9±1.3 after 3 h) associated with these regions was 
larger than httNT, but not as big as the roughness observed for the other 
phosphomimetic constructs. After 3 h of exposure, 54±1% of the bilayer surface was 
altered by httS16D.  
The relative trend of phosphomimetic mutations increasing the area of TBLE 
bilayers displaying altered morphology is roughly similar to the PDA assay; however, 
the extent of the increased interaction appears much larger with the PDA assay. This is 
likely due to the more pronounced morphological changes (as quantified by RMS 
roughness measurements) producing larger mechanical strain on PDA vesicles, 
amplifying the signal. A peculiar observation is that phosphomimetic mutations 
appeared to promote fibrillar htt aggregates on the TBLE surface; however, the ThT 
assays suggested that these mutations reduced fibrillization in the presence of TBLE 
vesicles. This may be due to differences in what is being monitored between the two 
assays. ThT measures aggregation in the entirety of the incubation (solution and 
membrane surface); however, in situ AFM only detects changes that appear on the 
membrane surface. As such, this suggests that there may be distinct aggregation 
pathways occurring simultaneously, one in bulk solution and one at the membrane 
interface. Such a notion is supported by EPR studies.32  
2.4 Discussion 
PolyQ expansion drives htt aggregation and toxicity, but flanking sequences 
adjacent to the polyQ domain heavily influence these processes.67–69 In particular, Nt17 
impacts htt localization, aggregation, and degradation in cells,17,45,48,70 and 
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phosphorylation within Nt17 further regulates these phenomena.37–39,71 Based on its 
ability to form an amphipathic α-helix, a key function of Nt17 is interacting and binding 
lipid membranes.32,70 Here, we investigated the impact of phosphomimetic mutations 
within the Nt17 on htt interaction and aggregation in the presence of a variety of model 
lipid membranes. In general, phosphomimetic mutations at T3, S13, or S16 slowed fibril 
formation in the presence of lipids; however, this was highly dependent on the specific 
lipid system used. As aberrant htt/lipid interactions and subcellular membrane damage 
are observed in HD, understanding how PTMs like phosphorylation impact htt/lipid 
interactions could reveal new therapeutic targets and strategies. 
 While the current study demonstrates that altering the charge of Nt17 via 
phosphomimetic mutations heavily influences htt aggregation in the presence and 
absence of lipids, there are several caveats to these studies that need to be addressed. 
Phosphomimetic mutations have been used to study the impact of phosphorylation on 
htt aggregation, and the consensus is that these mutations reduce fibrillization and fibril 
stability.37,39,47,50,51,54,72 However, such mutations are imperfect models of 
phosphorylation.73 Recent studies have explored the impact of bona fide 
phosphorylation within Nt17 on htt aggregation.74,75 Actual phosphorylation at S13 
and/or S16 impeded fibrillization and disrupted the α-helix formation in Nt17; S13D and 
S16D mutations did not strongly inhibit α-helix formation.74 This inhibited α-helix 
formation strongly reduced the interaction with lipid membranes. Phosphorylation at T3 
stabilizes α-helix formation.54 An additional caveat here is that only single 
phosphomimetic mutants were investigated. There is crosstalk between different PTM 
sites within Nt17 with implications for aggregation. Combinations of phosphorylation at 
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T3, S13, and S16 have profound impacts on Nt17 structure and htt aggregation.74 In 
addition, there is crosstalk associated between T3 and K6, with acetylation at K6 
reversing the inhibitory impact on htt aggregation associated with phosphorylation at 
T3.54 Despite these caveats, there is still value in using phosphomimetic mutations to 
understand how Nt17 phosphorylation regulates htt aggregation and membrane activity 
as introduction of phosphomimetic mutations (S13D/S16D) in the context of the full‐
length mutant htt improved phenotype in an HD mouse model.39 This suggests that, 
while phosphomimetic mutations may not provide exact models of the impact of 
phosphorylation of htt in HD, these mutations do modify phenotype and biophysical 
characterization can provide insights into potential toxic mechanisms. As such, 
understanding the biophysical impact of phosphomimetic mutations on htt aggregation 
and membrane activity may provide mechanistic detail concerning htt related toxicity. 
The differences in aggregation associated with the different lipid systems 
underscores the complexity of htt/lipid interactions. Experiments and simulations 
indicate that the structure and orientation of Nt17 on membranes is an amphipathic α-
helix that sequesters nonpolar residues toward the membrane hydrophobic core.76,77  
Electrostatic interactions between Nt17 and lipids influences the affinity of Nt17 for 
phospholipid bilayers,78,79 and a phosphomimetic double mutation (S13D and S16D) 
reduced the binding affinity of htt for POPC/POPS mixed lipid systems, requiring 15 
times the lipid content to reach saturation and suggesting an introduced electrostatic 
repulsion.26 Similar to what was observed here for aggregation in the presence of POPC 
or TBLE vesicles, the double mutation (S13D and S16D) suppresses htt aggregation 
with POPC/POPS vesicles.26  While we generally observed a large decrease in the 
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membrane binding of htt with phosphomimetic mutations with TBLE based on PDA 
assays, changes in membrane binding associated with phosphomimetic mutations 
observed here with POPC and POPG vesicles were subtle and often not significant. 
Beyond the use of different lipid systems between these studies, a potential explanation 
is that the single mutations used here only neutralized the net charge of Nt17 while the 
double mutation resulted in a net negative charge. Here, POPG enhanced aggregation 
even when the net charge of Nt17 was neutralized with little impact on htt membrane 
affinity. Taking into account that Nt17 contains numerous residues (T3, K6, K9, S13, 
K15, and S16) that can undergo charge altering PTMs34 and that crosstalk between 
these residues influence their modification and aggregation,54,74 modifying charge via 
combinations of PTMs in Nt17 can serve a potential role for targeting specific 
membranes of differing phospholipid composition. In this regard, phosphorylation and 
acetylation modifies the localization of huntingtin throughout cells.17,38,39,70,80,81 
The direct observation, via in situ AFM, that the introduction of phosphomimetic 
mutations in htt-exon1 altered the morphology of aggregates on supported TBLE bilayers 
further demonstrates the complex role interfaces play in these processes. While 
determining all the factors influencing aggregation in vivo remains difficult, a key 
component of the cellular environment is the presence of interfaces associated with 
membranes. Solid/liquid interfaces profoundly impact the aggregation process (both 
kinetically and morphologically) of numerous amyloid-forming proteins.82 For example, β-
amyloid peptide (Aβ) displays distinct aggregation pathways on chemically diverse 
surfaces. On the anionic surface of mica, Aβ forms small, highly mobile oligomers that 
coalesce into prefibrillar aggregates.83 In contrast, epitaxial effects associated with 
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exposure to graphitic surfaces promotes the formation of extended nanoribbons with 
distinct orientations on the surface.83 The introduction of point mutations clustered around 
the central hydrophobic core of Aβ (E22G Arctic mutation, E22K Italian mutation, D23N 
Iowa mutation, and A21G Flemish mutation) impact the rate of Aβ aggregation in bulk 
solution, but do not alter the morphology of aggregates once formed. However, these 
mutations have a pronounced impact on aggregate morphology when aggregation was 
directly observed on either mica84 or supported TBLE bilayers,64 demonstrating that a 
change in a single amino acid strongly influences protein/surface interactions. Regarding 
physiological relevance, cellular and subcellular membranes provide important quasi-
solid/liquid interfaces within cells. The ability of the lipid membranes to influence htt 
aggregation has been well established, with different lipid systems often having a distinct 
impact.22,32,33,85 Like the afore mentioned point mutations in Aβ, phosphomimetic 
mutations in htt-exon1 promoted distinct aggregate morphology on TBLE bilayers. This 
adds another layer of complexity when unraveling the heterogeneous mixture of 
aggregates forming in the cellular environment and assigning toxic function to specific 
aggregate forms. Htt/lipid interactions and factors modifying these interactions can have 
a pronounced impact therapeutic strategy aimed at modifying the aggregation process. 
In this regard, the presence of lipid membranes abolished the ability of the small molecule 
curcumin from inhibiting htt fibrillization.85   
 Understanding the interplay between htt and membranous surfaces is critical for 
understanding a variety of associated toxic mechanisms. A number of biophysical 
functions are associated with  lipid binding amphipathic α-helices86 such as Nt17. These 
include detecting and binding highly curved lipid membranes,87,88 and Nt17 
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demonstrates this propensity.26,31 Amphipathic α-helixes bind membranes weakly and 
are regulated by a variety of PTMs. Phosphorylation in Nt17 appears to perform such a 
regulatory role in cellular trafficking of htt,37,39,71,74 suggesting that phosphorylation plays 
a role in the selectivity of htt binding to a variety of subcellular membranes of varying 
lipid composition. The impact of phosphorylation to stabilize or destabilize α-helix 
formation is one contributing factor in altering htt’s affinity for membranes,74 but 
selectivity likely works in conjunction with membrane composition. Lipid composition 
determines the physicochemical properties of membranes that influence 
amyloid/membrane interactions.82  Beyond electrostatic considerations, the 
aforementioned propensity of Nt17 for curved membranes suggest that selectivity of htt-
exon1 for different membranes may be related to lateral membrane pressure and 
transient packing defects, both of which are readily influenced by curvature.89 The 
introduction of phosphomimetic mutations, especially T3 and S13, enhanced the affinity 
of htt for TBLE, yet TBLE strongly inhibited fibril formation while stabilizing oligomer 
size. The complexity of TBLE, which is comprised of a complex, physiologically relevant 
ratio of zwitterionic and negatively charged lipids (9.6% phosphatidylcholine, 16.7% 
phosphatidylethanolamine, 1.6% phosphatidylinositol, 10.6% phosphatidylserine, 2.8% 
phosphatidic acid, etc.), provides a varied surface that provides an array of transient 
defects to interact with Nt17. TBLE also contains ~20-25% cholesterol, which 
significantly alters htt aggregation on membranes.22 In this regard, brain extracts 
promote α-helical structure within Nt17.27 The affinity of htt for POPC and POPG was 
less impacted by phosphorylation, suggesting that tuning of membrane affinity of htt-
exon1 by phosphorylation is more sensitive to complex lipid membranes. 
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Huntington’s disease (HD) is a fatal neurodegenerative disease caused by an extended 
polyglutamine (polyQ) domain within the first exon of the huntingtin protein (htt). PolyQ 
expansion directly invokes the formation of a heterogenous mixture toxic htt aggregates, 
including fibrils and oligomers. While htt is a cytosolic protein, it also associates with 
numerous organelle surfaces within the cell, leading to altered organelle morphology 
and dysfunction. Here, the impact of macromolecular crowding on htt aggregation in 
bulk solution and at solid/liquid or membrane/liquid interfaces was investigated. 
Dextran, ficoll, and polyethylene glycol (PEG) were used as crowding agents. In bulk 
solution, crowding enhanced the heterogeneity of non-fibrillar aggregate species formed 
in a crowder dependent manner. Crowding agents interfered with the deposition and 
formation of htt fibrils on mica. Crowding in the aqueous phase enhanced deposition of 
htt aggregates onto supported total brain lipid extract (TBLE) supported bilayers, 
leading to distinct morphological alteration of the bilayer surface. Collectively, these 
observations point to the complexity of htt aggregation at interfaces and that crowding in 
the aqueous phase profoundly influences this process. 
3.1 Introduction 
Deposition of aggregated, proteinaceous material as plaques and inclusions is a 
hallmark of several neurodegenerative diseases, i.e. Parkinson’s disease (PD), 
Alzheimer’s disease (AD), and Huntington’s disease (HD). These deposits are 
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predominately comprised of amyloid, characterized by a fibrillar morphology and cross 
β-sheet structure. Of these diseases, HD is caused by a mutation in the huntingtin gene 
that encodes for an abnormal expansion (greater than ~35 repeats) of a polyglutamine 
(polyQ) tract in the first exon of the huntingtin protein (htt).1 PolyQ expansion correlates 
with htt aggregation, which is a multi-pathway, complex process involving a variety of 
aggregate species including oligomers, amorphous aggregates, fibrils, and annular 
structures.2–4  Due to the variety of aggregates possible, htt aggregation results in 
heterogeneous mixtures of aggregates, making it difficult to elucidate relationships 
between structure and toxic gain of function. Fibrils,5,6 oligomers,7–9 and inclusions10 are 
all implicated as potential toxic entities. Due to this, it is imperative to understand how 
exogenous factors within the cytosolic environment influence aggregation. 
While aggregation is a heterogeneous process, the complexity of the intracellular 
environment can have a pronounced impact on htt aggregation. The cytosolic 
environment of cells is extremely crowded with proteins and other large 
macromolecules. Depending on location and cell type, macromolecular concentrations 
within cells can reach up to 400 mg/mL and up to 40% of the available volume is 
occupied by macromolecules,11–14 and such crowded environments influence protein 
behavior.15 For example, macromolecular crowding agents sterically reduce 
configurational entropy in proteins via an excluded volume mechanism.16 In addition, 
proteins nonspecifically interact with crowding agents via van der Waals forces, 
hydrophilic/hydrophobic effects, and electrostatics.17 These interactions further influence 
protein conformation. As such, the physicochemical properties of the crowder molecules 
profoundly influence proteins in numerous ways with implications for amyloid 
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formation.18 Amyloid formation in a crowded environment can differ by orders of 
magnitude from that observed in bulk solution.16,19 The impact of crowders on different 
amyloid-forming proteins varies greatly depending on factors such as crowder 
concentration, and the extent of interaction between the crowding agent and the 
aggregating protein. For example, α-synuclein aggregation is accelerated by numerous 
crowders, i.e. polyethylene glycol (PEG), dextran, ficoll, lysozyme, and bovine serum 
albumin; however, larger macromolecular crowders promoted aggregation faster than 
smaller crowders.20 On the other hand, crowders can stabilize multimeric protein states, 
suppressing nucleation of fibrillization.21 In terms of chemical interactions, the extent of 
saccharide based crowders interaction with Aβ determined whether crowding promoted 
or inhibited fibril formation.22 
Beyond crowded environments, the presence of liquid/surface interfaces alter 
amyloid formation.23 Solid surfaces,24,25 including mica, graphite, gold, and Teflon, 
induce conformational changes in proteins, which alter aggregation of a variety of 
amyloid forming proteins.26–30 Surfaces of particular physiological relevance are lipid 
membranes, which also exert influence on protein aggregation.23 In this regard, htt is 
highly associated with membranous surfaces within cells, and these interactions further 
modify aggregation.  For example, htt and a variety of its aggregated forms localize to 
the ER, mitochondria, nuclear envelope, tubulovesicles, endosomes, lysosomes, and 
synaptic vesicles.31–35 PolyQ expansion enhances htt/phospholipid interactions.36–38 Htt 
aggregation disrupts lipid membranes, leading to organelle dysfunction.30,39–41 Brain 
lipids and membranous structures accumulate in htt aggregates,39,42–44 suggesting a 
role of lipids in the aggregation process. Indeed, the impact of a variety of membranes, 
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ranging from total brain lipid extracts (TBLE) to pure lipid systems, alter the rate of 
aggregation and the resulting aggregate species observed.30,45–48 Htt-exon1 fibril 
formation is enhanced in the presence of POPC/POPS45,49,50 mixed vesicles and pure 
POPC, POPG, or POPS vesicles.51 On the other hand, brain lipid extracts reduce 
fibrillization,30,38,52 and the addition of exogenous lipid components, i.e.  cholesterol, 
sphingomyelin, and GM1,47,48  to these extracts further influence aggregation.   
Here, the impact of macromolecular crowding on htt aggregation was 
investigated. Three different crowders (Dextran, Ficoll, and polyethylene glycol (PEG)) 
were used. In particular, the impact of macromolecular crowding in the aqueous phase 
on htt aggregation and solid/liquid or membrane/liquid interfaces was determined. 
Continuous imaging using in situ atomic force microscopy (AFM), allowing for the 
tracking of individual aggregates on surfaces, monitored aggregation at these 
interfaces. Despite the different macromolecular crowders being considered chemically 
inert,53,54 each exerted differing influence on htt aggregation in bulk solution with Ficoll 
promoting a unique aggregate morphology. While ThT assays suggested that fibrils still 
formed, crowders interfered with fibril deposition onto mica. When monitoring 
aggregation occurring directly on mica, a variety of oligomers and fibrils were observed, 
but the extent of surface aggregation was impeded by crowding in the aqueous phase, 
with PEG completely blocking the observation of fibrils. When supported total brain lipid 
extract (TBLE) bilayers were exposed to htt, crowding in the aqueous phase by all three 
macromolecules enhanced htt deposition on the bilayer, resulting in increased 
membrane morphological disruption. Here, PEG was associated with the most 
aggressive extent of membrane damage. 
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3.2 Materials and Methods 
3.2.1 Expression, Purification of (GST)-htt-exon1 Fusion Protein. A (GST)-htt-
exon1(46Q) fusion protein was purified as described previously.55 In short, GST-htt-
exon1 was expressed in E. Coli. Resulting cells were lysed with lysozyme (0.5 mg/mL) 
and probe sonication. The target fusion protein was purified from these lysates using a 
GST affinity column and liquid chromatography (BioLogic LPLC, Bio Rad). The purity of 
the target protein in relevant Fractions was assessed by SDS-PAGE. Protein 
concentration was determined by a Bradford assay. Prior to each experiment, pre-
existing aggregates were removed via high speed centrifugation (20,000 ×g at 4°C for 
30 minutes). Factor Xa protease (New England Bio Labs) was used to cleave GST and 
initiate aggregation. All experiments were performed in Tris buffer (50mM Tris-HCl, pH 
7, 150mM NaCl). 
3.2.2 Macromolecular Crowder Preparation. Stock solutions (800 mg/mL) of Ficoll 
400, Dextran 20,000, and Polyethylene Glycol 20,000 (PEG) of macromolecular 
crowders were made in Tris buffer heated to 60°C, resulting in viscous solutions. These 
solutions were incubated in an orbital thermomixer at 60°C and 1400 rpm, followed by 
bath sonication at 60°C for 1h. These stock solutions were diluted to reach the final 
desired crowder concentrations in various experiments. 
3.2.3 Peptide Preparation. A custom, synthetic peptide based on htt-exon1, 
Nt17Q35P10KK (AnaSpec) was prepared based on a variation of previously described 
protocols.56  Briefly, peptide was dissolved in a 1:1 mixture of hexafluoroisoproponal 
(Acros Organics) and trifluoroacetic acid (Acros Organics) for 12 h without agitation. 
Excess solvent was evaporated off using a vacufuge. The resulting films were dissolved 
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in DMSO at a concentration of 2000 µM. These DMSO stock solutions were diluted into 
Tris buffer (20 µM, 1% DMSO), and this solution was injected directly into the AFM fluid 
cell (final concentration of 10 µM, 0.5% DMSO). 
3.2.4 Lipid Vesicle Preparation. Total brain lipid extract (TBLE; Avanti Polar Lipids) 
was hydrated in Tris buffer with vortex mixing at 60°C until all lipid was suspended in 
solution. Vesicle formation was promoted by 10 freeze/thaw cycles using liquid nitrogen, 
followed by bath sonication for 1 hour at room temperature. The vesicle size distribution 
was analyzed by dynamic light scattering (NanoBrook Omni particle size analyzer, 
Brookhaven). 
3.2.5 Thioflavin T (ThT) Aggregation Assay. Htt-exon1(46Q) was diluted to a final 
concentration of 10 µM in the presence of 125 µM ThT (Sigma-Aldrich, St. Louis, MO). 
Assays were performed in a 96-well plate format (100 µL per well) using a microplate 
reader (Molecular Devices, SpectraMax M2). All assays were run at 37°C, and readings 
were taken every 5 min with 440 nm excitation and 484 nm emission. All conditions 
were run in triplicate with a minimum of three independent experiments performed. In 
ThT assays with lipids, a 10:1 lipid:protein ratio was used. 
3.2.6 Polydiacetylene (PDA) Vesicle Binding Assay. 10,12-tricosadiynoic acid (GFS 
Chemicals, Columbus, OH) and TBLE was dissolved at a 2:3 molar ratio in a solution of 
1:4 ethanol/chloroform. Excess solution was evaporated off under a stream of N2, and 
the resulting film was resuspended in Tris buffer at 70°C. Probe sonication (10-minute 
intervals at 100 W) using a sonic dismembrator (FisherSci) was performed to achieve 
an opaque solution. This solution was stored at 4°C overnight to allow self-assembly 
into vesicles. Polymerization of the PDA was initiated by irradiation at 254 nm for 10 
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minutes at room temperature with stirring, resulting in a blue color. The assay was 
performed in a 96-well plate format using a microplate reader (Molecular Devices, 
SpectraMax M2). The percent colorimetric response (% CR) was determined every 5 
min by measuring the blue absorbance (640 nm, Ablue) and the red absorbance (500 
nm, Ared) using the following equation.  
  
(𝐸𝐸𝐸𝐸𝐸𝐸. 3.1)         % 𝐶𝐶𝐶𝐶 = �
𝑃𝑃𝐵𝐵0 − 𝑃𝑃𝐵𝐵1
𝑃𝑃𝐵𝐵0
� ∗ 100 
 
PB is defined as Ablue/(Ablue+Ared).57,58 PB0 was determined from the negative control of 
exposure of the vesicles to neat buffer, and  PB1 was obtained is obtained from each 
experimental condition. A positive control of exposure to 100 µM NaOH was performed 
and used to standardize the PDA assays across independent trials.59 All conditions 
were run in triplicate with a minimum of three independent experiments performed. 
3.2.7 Atomic Force Microscopy (AFM). For ex situ AFM experiments, htt-exon1(46Q) 
(10 µM) was incubated in the presence and absence of macromolecular crowders at 
37°C and 1400 rpm in an orbital thermomixer. At designated time points, 2 μL aliquots 
of each sample were deposited onto freshly cleaved mica (Ted Pella Inc., Redding, CA) 
for 1 minute, washed with 200 μL of 18 MΩ ultrapure water, and dried under a gentle 
stream of filtered air. For the fibril deposition experiment, htt-exon1(46Q) (20 µM) was 
incubated at 37°C and 1400 rpm in an orbital thermomixer for 24 h to pre-form fibrils. An 
aliquot of this sample was diluted into neat buffer (control) or macromolecular crowders 
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to achieve a final concentration of 10 µM of htt and 100 mg/mL of each crowder. These 
samples were deposited on mica as described above. All samples were imaged using a 
Nanoscope V Multi-Mode scanning probe microscope (VEECO) equipped with a closed 
loop vertical engage J-scanner and silicon-oxide cantilevers with a resonance frequency 
of ~300 kHz and a nominal spring constant of 40 N/m. For in situ AFM experiments, a 
tapping mode fluid cell equipped with an O ring and cantilever with a nominal spring 
constant of 0.1 N/m were used. For experiments of peptide aggregation on mica, 
samples of peptide (10 µM) in neat buffer or with macromolecular crowders (100mg/mL) 
were mixed and injected directly into the fluid cell. Aggregation on mica was monitored 
by continuous imaging. For experiments on lipid membranes, prepared vesicles were 
injected into the fluid cell and allowed to fuse onto the surface to form a supported 
bilayer. Once a continuous 40 µm x 40 µm patch of supported lipid bilayer formed, htt-
exon1(46Q) that had been incubated on ice with factor Xa for 1 h was injected with and 
without macromolecular crowders into the fluid cell for a final concentration of 10 µM of 
htt and 25 mg/mL of crowders. Aggregation on the bilayer was monitored by continuous 
imaging. For in situ AFM experiments on mica or supported bilayers, scan size was 
periodically increased to ensure that the imaging process was not influencing 
aggregation. All AFM images, from both ex situ and in situ experiments, were analyzed 
using MATLAB equipped with the image processing toolbox (MathWorks) as 
described.60,61  
3.3 Results 
3.3.1 Crowding alters htt aggregation in bulk solution. To investigate the impact of 
macromolecular crowders on htt aggregation in bulk solution, a GST-htt-exon1 fusion 
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protein with 46 repeat glutamines (htt-exon1(46Q)) was used as a model system. 
Cleavage of the GST tag with Factor Xa initiates aggregation. Htt-exon1(46Q) (10 µM) 
was incubated in the presence of Dextran (20,000 da), Ficoll (400 da), or PEG (20,000 
da), and fibril formation was monitored with a ThT assay (Figure 1). A concentration 
gradient (50, 100, and 200 mg/mL) was investigated for each crowder. For most 
conditions, there were not statistically significant changes in fibril formation compared to 
htt-exon1(46Q) incubated in the absence of crowders; although, there were some 
trends associated with each crowder. With dextran, ThT signal was typically larger than 
control, but this was only significantly different with 200 mg/mL dextran when comparing 
the maximum ThT signal (p < 0.05). Ficoll also appeared to increase fibril formation with 
increasing crowder concentration; however, the 200 mg/mL ficoll condition did not quite 
reach statistical significance. Unlike in the presence of the other two crowders, htt 
aggregation appeared slightly reduced in the presence of PEG, but this reduction did 
not reach statistical significance under any condition. 
Figure 3.1: The impact of macromolecular crowders on htt-exon1(46Q) fibril formation as 
assessed by a ThT assay. Macromolecular crowders used were (A) dextran, (B) ficoll, and (C) 
PEG, and each was investigated at 50 mg/mL, 100 mg/mL, and 200 mg/mL. Htt-exon1(46Q) 
concentration was 20 µM. Buffer control represents experiments without any crowding agent. 
Error bars represent standard error of the mean (SEM) and are provided every 30 min. 
 
 While the three crowders did not have a pronounced impact of fibril formation as 
measured by a ThT assay, this assay does not provide information concerning fibril 
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morphology or other non-fibrillar aggregates such as oligomers. To determine if 
crowding impacted fibril morphology and oligomer formation, htt-exon1(46Q) 
incubations with macromolecular crowders and sampled after 8 h for AFM analysis. Htt-
exon1(46Q) incubations in the absence of crowders were monitored as a control. 
Representative AFM images of these incubation with 100 mg/mL of each crowder are 
shown in Figure 2A, with background images of each crowder (no htt-exon1) deposited 
on mica are shown in Figure 3. Representative AFM images of htt-exon1(46Q) with 
other concentrations (50 mg/mL and 200 mg/mL) of the crowders are presented in 
Figure 4. Based on the ThT assays, we expected to see significant populations of htt 
fibrils under all conditions; however, fibrils were only observed in the control incubation 
(Figure 2A). As a result, a control experiment was designed to determine if the crowders 
interfered with the deposition of fibrils onto mica (Figure 2B). 20 µM htt-exon1(46Q) 
solutions were seeded with pre-formed fibrils and incubated to obtain extensive fibril 
populations. These pre-aggregated htt-exon1(46Q) samples were diluted to obtain a 
final protein concentration of 10 µM with either neat buffer containing no crowding 
agents or with macromolecular crowders at a final concentration of 100 mg/mL. After 5 
min of mixing, these solutions were sampled and deposited on mica for AFM analysis of 
fibril coverage. Comparison of the number of fibrils per unit area for each sample 
demonstrated that all three crowders prevent fibrils from depositing on mica to a 
significant extent (Figure 2C). PEG had the largest impact on the fibril density on mica, 
reducing it by 92%, followed by ficoll (73% reduction) and dextran (49% reduction). This 
analysis suggests that the absence of fibrils observed from incubations of htt-
exon1(46Q) with each crowder may be due to interference with the deposition process. 
Chapter 3 | 74  
 
 Despite the crowders interfering with fibril deposition, the different 
macromolecular crowders promoted distinct morphologies of non-fibrillar aggregates 
that adhered to mica (Figure 2A). To quantify this altered morphology, the height and 
diameter of each non-fibrillar aggregate was measured using automated scripts in 
MATLAB60,61 and used to construct height vs diameter correlation plots (Figure 2D). To 
verify that features observed in the AFM images derived from htt-exon1(46Q) were 
unique to the addition of protein, control crowder background images (Figure 4) were 
analyzed and also plotted in the correlation plots for comparison. Htt-exon1(46Q) in 
neat buffer formed a heterogeneous mixture of globular oligomers with heights ranging 
predominately from 1-8 nm and diameters ranging from ~30-80 nm. While the dextran 
background contained numerous features (heights ~1-5 nm, diameters ~30-60 nm) that 
overlapped with the size of the smaller htt-exon1 oligomers, a unique set of significantly 
larger globules were observed in incubations of htt-exon1(46Q) incubated with dextran 
at 100 mg/mL. These large globules displayed tighter correlation between their heights 
and diameters with a significant population growing beyond the range (height > 10 nm, 
diameters > 80 nm) of features observed in the htt-exon1 control. These larger 
aggregates associated with htt-exon1 aggregation in the presence of dextran were 
present in the 50 mg/mL sample but were not observed at dextran concentration of 200 
mg/mL.  
Analysis of htt oligomers formed in the presence of ficoll is complicated due to 
the extensive features appearing in the ficoll blank control that had significant overlap 
with features observed when htt-exon1(46Q) was incubated with ficoll at 100 mg/mL. 
However, there was a clearer shift of features distinct from the background at 50 mg/mL 
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and 200 mg/mL ficoll experiments. Nevertheless, the distribution of potential htt-
exon1(46Q) oligomers in the correlation plots associated with the presence of ficoll are 
distinct to those observed in the htt-exon1(46Q) control. With htt-exon1(46Q), very few 
features appeared on the mica surface in the presence of PEG, and few features 
appeared as background from control PEG experiments. However, observed oligomers 
of htt-exon1(46Q) formed in the presence of PEG at 100 mg/mL displayed a “fried egg” 
like morphology. That is, a flat feature around the periphery of each aggregated 
surrounded a distinct globular structure in the middle. While the measured height of 
these features were similar to oligomers observed in control htt-exon1(46Q) 
incubations, their diameters were significantly larger (60-120 nm) due to the peripheral 
portion of the aggregate. While ThT did not detect any difference associated with fibril 
formation and elongation, AFM images suggest that each crowder altered the 
morphology of aggregate intermediates to varying extent. This observation is limited, 
however, to the htt-exon1(46Q) aggregates that readily deposited on mica. 
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Figure 3.2: Ex situ AFM analysis of htt-exon1(46Q) aggregates formed in the presence of 
100 mg/ML macromolecular crowders. Htt-exon1(46Q) was incubated at 20 µM with dextran, 
ficoll, or PEG. These incubations were sampled for AFM imaging after 8 h of incubation, and (A) 
representative AFM images are presented. (B) Preformed htt-exon1(46Q) fibrils were mixed 
with 100 mg/mL macromolecular crowders, deposited on mica, and imaged by AFM to 
determine if the crowders interfered with the deposition of fibrils. (C) Quantification of the fibrils 
observed per unit area on mica from the fibril deposition experiment in (B). Error bars represent 
standard error of the mean (SEM), and * indicated p < 0.01. (D) Correlation plots of height vs 
diameter of non-fibrillar aggregates observed in (A). For each correlation plot, features observed 
in the corresponding blank (crowder only) control are provided for comparison. 
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Figure 3.3: Representative AFM images of mica exposed to (A) neat buffer or 100mg/mL of 
either (B) dextran, (C) ficoll, or (D) PEG. Height profiles, as indicated by the green lines, are 
provided below each image. 
 
 
Figure 3.4: Ex situ AFM analysis of htt-exon1(46Q) aggregates formed in the presence of 
50 or 100 mg/ML macromolecular crowders. Htt-exon1(46Q) was incubated at 20 µM with 
dextran, ficoll, or PEG. These incubations were sampled for AFM imaging after 8 h of 
incubation, and (A) representative AFM images are presented. (B) Correlation plots of height vs 
diameter of non-fibrillar aggregates observed in (A). For each correlation plot, features observed 
in the corresponding blank (crowder only) control are provided for comparison. 
 
3.3.2 Htt aggregation at a solid/liquid interface is modified by macromolecular 
crowders. As all three crowders interfered with fibril deposition onto mica and were 
associated with unique oligomeric species appearing on mica, it is possible that a 
crowded liquid phase alters the interaction of htt-exon1 with mica. As a result, we next 
aimed to elucidate if macromolecular crowding in the aqueous phase influenced 
aggregation occurring at a mica surface. Due to complications associated with the GST 
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tag, a synthetic htt peptide that mimics htt-exon1 was used. This peptide was comprised 
of the first N-terminal 17 amino acids (Nt17) of htt that precede the polyQ domain, a 
polyQ domain of 35 repeats, a polyP stretch of 10 residues, and two lysine residues at 
the C-terminus to aid in solubility. Due to this, the peptide is referred to as Nt17-Q35-P10-
KK. The real-time aggregation of Nt17-Q35-P10-KK  on mica was tracked by continuous 
in situ AFM imaging (Figures 5 and 6). Solutions of Nt17-Q35-P10-KK  were prepared in 
neat buffer or with crowders and injected directly into the AFM fluid cell to a final protein 
concentration of 10 μM and crowder concentration of 100 mg/mL.   
 
Figure 3.5: Tracking of individual Nt17-Q35-P10-KK aggregates in mica as a function of 
time with no crowders in the aqueous phase. (A) A series of in situ AFM images of the same 
regions on mica. Black circles indicate aggregates in consecutive images that were initially 
classified as oligomers that remain stable or eventually transition into fibrils. Green circles 
identify oligomers in consecutive images that eventually desorb from the mica surface. The blue 
box indicates in consecutive images two fibrils that grow together. (B) Analysis of the time that 
128 distinct oligomers remained stable on mica. 
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Figure 3.6: Comparison of Nt17-Q35-P10-KK aggregation on mica with different 
macromolecular crowders in the aqueous phase. (A) Time-sequence, representative in situ 
AFM images of Nt17-Q35-P10-KK (10 µM) aggregating on mica with buffer, dextran, ficoll, or 
PEG in the aqueous phase. The macromolecular crowder concentration was 100 mg/mL. As the 
height of features varied, the blue boxes represent areas of the image that correspond to the 
color scale with blue font. (B) Quantification of the % surface area covered by Nt17-Q35-P10-KK 
aggregates as a function of time. Error bars represent standard deviation.  
 
Nt17-Q35-P10-KK in neat buffer (no crowders) formed a variety of oligomers and 
putative fibrils on mica within the timeframe of the first image (~8-10 minutes after 
injection, Figure 5 and 6A). The mica area occupied by these Nt17-Q35-P10-KK 
aggregates steadily increased with time, and the predominate aggregate species on the 
surface were fibrillar in morphology within 17-20 minutes. These fibrillar species grew in 
length from both ends as more peptide was incorporated into the aggregate. Branching 
was often observed, and fibrils growing into each other frequently occurred (Figure 5A). 
Several of these fibrils had clear oligomer precursors, but the majority of them did not. 
That is, they already had a fibrillar morphology upon their initial appearance. There were 
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several observed mechanisms for oligomer disappearance. Some oligomers 
transitioned into fibrils, some desorbed from the mica surface, and others were 
incorporated into a pre-existing fibril that extended toward the oligomer. The relative 
stability of individual oligomers varied greatly. The fate of 128 individual oligomers were 
tracked from image to image to determine how long each remained in an oligomer 
conformation on the mica surface (Figure 5B). Just under half of these oligomers 
disappeared within ~10 minutes (or by the next image). However, ~10% of identified 
oligomers persisted for over an hour on mica. The total amount of aggregation on mica 
was quantified by determining the percent surface area occupied by aggregates as a 
function of time (Figure 5B). Based on this analysis, total aggregation of Nt17-Q35-P10-
KK  in neat buffer steadily grew, covering 39.2 ± 2.9% of the mica surface after ~200 
min. 
 With the addition of macromolecular crowders in the aqueous phase, aggregation 
of Nt17-Q35-P10-KK  on mica was significantly reduced (Figure 6A). With dextran and 
ficoll, a smaller number of aggregates (both oligomers and putative fibrils) appeared 
within 8-10 min compared to control. With time, fewer additional aggregates appeared 
on mica. The aggregates that did appear were mostly fibrillar and their morphology was 
indistinguishable to control. These fibrils elongated and branched with time. However, 
the extent of aggregation on the surface was significantly diminished, as only 2.6 ± 
0.5% and 5.6 ± 3.7% of the mica surface was occupied by aggregates after ~200 min 
(Figure 6B). With PEG, fibrils were not observed on mica, and only a few oligomers 
were present (occupying less than 0.5% of the total surface for over 200 min; Figure 
6B). The observed oligomers in the presence of PEG were typically smaller than 
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oligomers observed under all other conditions; however, very few of these small 
oligomers were observed across all trials with PEG, making comparisons difficult. 
3.3.3 Htt aggregation on lipid bilayers is modified by macromolecular crowders. 
As crowders altered htt peptide aggregation at a solid/liquid interface and lipid 
membranes can also impact amyloid formation, the ability of crowders in the aqueous 
phase to impact htt-exon1(46Q) on lipid bilayers was investigated. The model lipid 
system chosen for these studies was total brain lipid extract (TBLE) because it contains 
a physiologically relevant mixture of lipid components. To determine if the 
macromolecular crowders altered the ability of htt-exon1(46Q) to bind lipid membranes, 
TBLE/PDA vesicle lipid binding assay was performed (Figure 7). This is a colorimetric 
assay in which vesicles comprised of a mixture of phospholipids and polymerized PDA 
exhibit a rapid color change from blue to red due to mechanical stress induced by 
protein binding. By monitoring the %CR peptide–membrane interactions and interfacial 
membrane processes can be quantified. First, each macromolecular crowder (at 
concentrations of 50, 100, and 200 mg/mL) was tested to see if they invoked a CR in 
the TBLE/PDA vesicles in the absence of htt (Figure 8). The crowders did not invoke a 
CR in the absence of protein. Next, TBLE/PDA vesicles were exposed to htt-
exon1(46Q) at 10 µM in the presence of each crowder at the various concentrations, 
and the %CR was measured over 9 h (Figure 7). Relative to control (htt-exon1(46Q) in 
the absence of crowders), all three crowders typically enhanced htt-exon1(46Q) 
interaction with TBLE vesicles. For dextran, the largest enhancement was observed at 
50 mg/mL crowder concentration. At higher concentrations of dextran, htt-exon1(46Q) 
lipid binding was enhanced relative to control to a lesser extent. A similar trend was 
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observed with Ficoll, as the lower concentrations of ficoll induced larger %CRs. 
Although, 200 mg/mL ficoll resulted in an initial jump in the %CR that was followed by a 
slight reduced %CR compared to control. PEG, at all concentrations, invoked an initial 
large response that dropped off after ~1-2 h. After this time frame, the %CR either did 
not increase or tracked closely with control. A caveat is that the combination of PEG 
and htt-exon1(46Q) often caused the TBLE/PDA vesicles to fall out of solution, 
suggesting that the large initial response was destabilizing the suspension and causing 
the smaller measured %CR. Nevertheless, the assay suggests that all three crowders 
enhanced the ability of htt-exon1(46Q) to bind vesicles. 
 
 
Figure 3.7. The impact of macromolecular crowders on htt-exon1(46Q) interaction with 
TBLE vesicles as assessed by a PDA assay. Macromolecular crowders used were (A) dextran, 
(B) ficoll, and (C) PEG, and each was investigated at 50 mg/mL, 100 mg/mL, and 200 mg/mL. 
Htt-exon1(46Q) concentration was 20 µM. Buffer control represents experiments without any 
crowding agent. Error bars represent standard error of the mean (SEM) and are provided every 
30 min. 
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Figure 3.8. Control TBLE/PDA lipid binding assays assessing if macromolecular 
crowders invoke a colorimetric response. Macromolecular crowders used were (A) dextran, 
(B) ficoll, and (C) PEG, and each was investigated at 50 mg/mL, 100 mg/mL, and 200 mg/mL.  
 
 As the macromolecular crowders altered the ability of htt-exon1(46Q) to interact 
with lipid vesicles, we next used a ThT assay to assess if these crowders altered fibril 
formation in the presence of TBLE vesicles (Figure 9). To further assess the impact of 
the crowders on fibrillization of htt, for these assays, the lipid to htt molar ratio was 10:1, 
and the vesicles were ~140-180 nm in diameter as assessed by dynamic light 
scattering. The impact of the three crowders on fibril formation in the presence of TBLE 
vesicles as assessed by ThT followed a similar trend as that observed in the absence of 
TBLE vesicles. That is, dextran and ficoll appeared to increase fibrillization; PEG 
appeared to slightly inhibit fibrillization. However, with the addition of both vesicles and 
crowders, the noise in these assays was increased, and these differences did not reach 
statistical significance. However, the ThT assay comprehensively measures fibril 
formation of the entire sample and cannot distinguish between fibrils formed in bulk 
solution or at the vesicle surface. It also does not provide information regarding non-
fibrillar aggregates. 
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Figure 3.9. The impact of macromolecular crowders on htt-exon1(46Q) fibril formation in 
the presence of TBLE vesicles as assessed by a ThT assay. Macromolecular crowders used 
were (A) dextran, (B) ficoll, and (C) PEG, and each was investigated at 50 mg/mL, 100 mg/mL, 
and 200 mg/mL. Htt-exon1(46Q) concentration was 20 µM. TBLE vesicles were added at a lipid 
to peptide ratio of 10:1. Buffer control represents experiments without any crowding agent. Error 
bars represent standard error of the mean (SEM) and are provided every 30 min. 
  
To more directly investigate htt-exon1(46Q) aggregation on TBLE bilayers, in situ 
AFM was employed to observe aggregation occurring on a supported TBLE bilayer with 
a crowded aqueous phase (Figure 10). For these experiments, it is important that the 
supported bilayer is stable under continuous imaging. Therefore, control experiments 
were performed to verify that bilayers were stable when crowders were injected into the 
fluid cell. Supported bilayers were first formed on mica in neat buffer, and then 
macromolecular crowders were injected into the fluid cell. Based on these control 
experiments, it was determined that the supported bilayers were reliably imaged with up 
to 25 mg/mL of crowder in the fluid cell for several hours. Larger concentrations of 
crowders often resulted in membrane damage. As a result, these experiments were 
performed with a 25 mg/mL final concentration of crowding macromolecules. Only 
continuous TBLE bilayers (40 × 40 μm in size), as assessed by AFM imaging in neat 
buffer, were exposed to htt-exon1(46Q), and observations were limited to these verified 
continuous bilayers. A freshly prepared TBLE bilayer had an RMS roughness of 
0.26±0.06 nm prior to being exposed to htt-exon1(46Q) (Figure 10B). Htt-exon1(46Q) 
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was injected to a final concentration of 10 µM in the fluid cell. For experiments with 
crowders, htt-exon1(46Q) and the crowder were mixed together and injected into the 
fluid cell at the same time. 
 
Figure 3.10. Comparison of htt-exon1(46Q) aggregation on supported TBLE bilayers with 
different macromolecular crowders in the aqueous phase. (A) Time-sequence, 
representative in situ AFM images of htt-exon1(46Q) (10 µM) aggregating on supported TBLE 
bilayers with buffer, dextran, ficoll, or PEG in the aqueous phase. The macromolecular crowder 
concentration was 25 mg/mL.  As the height of features varied, the blue boxes represent areas 
of the image that correspond to the color scale with blue font. (B) Quantification of the RMS 
roughness of unperturbed (solid bars) and disrupted (striped bars) regions of the bilayer. The 
RMS roughness of a bilayer prior to exposure to htt-exon1(46Q) is provided by the purple bar. 
Error bars represent standard deviation. (C) Height and diameter histograms of htt-exon1(46Q) 
aggregates as a function of time. (D) Quantification of the % area of the bilayer disrupted by htt-
exon1(46Q) as a function of time. Error bars represent standard deviation. 
 
 When TBLE was exposed to htt-exon1(46Q) in the absence of crowders, 
numerous oligomers appeared on the surface within 10 min, and often small defects in 
the bilayer were observed (Figure 10A). With time, regions of the bilayer displayed 
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disrupted morphology characterized by increased surface roughness and a highly 
granular appearance. Most of the bilayer maintained a smoother appearance. Often, 
these roughened areas developed around previously observed oligomers. These 
disrupted regions grew in area and became rougher with time. To quantify this 
roughening effect, regions of the bilayer displaying increased roughness were identified 
and the RMS roughness of these regions was determined (Figure 10B). The RMS 
roughness of the unaltered regions of the bilayer was also determined. The roughness 
of the smooth regions was comparable to freshly prepared TBLE bilayers. However, the 
RMS roughness of the disrupted portion of the membrane was 0.57±0.13 nm after ~9 
min, and this increased to 1.22±0.33 nm after ~140 min. The dimensions of the 
oligomers observed were also measured, and these oligomers swelled in size 
(predominately in the lateral dimension) with time (Figure 10C). To quantify the extent of 
the interaction of htt-exon1(46Q) with the supported bilayers, the percentage of the 
surface that displayed any altered morphology was determined as a function of time via 
AFM image analysis (Figure 10D). For this analysis, the area occupied with aggregates 
was considered as a disrupted region. After ~130-145 min, the extent of the bilayer 
disrupted leveled off at about 13-15% of the total bilayer area.  
The interaction and aggregation of htt-exon1(46Q) with the supported TBLE 
bilayers was altered by the addition of macromolecular crowders in a crowder 
dependent manner. When the aqueous phase was crowded with dextran, oligomers 
appeared on the surface within the first 10 min of exposure to htt-exon1(46Q) in a 
similar fashion to the control experiment without crowders, and these oligomers 
increased in size with time (Figure 10A). Similar to control, regions of increased 
Chapter 3 | 87  
 
roughness with a granular appearance also developed on the bilayer, except these 
regions occupied more of the surface area with time (Figure 10C), and the RMS 
roughness of these regions became larger after ~100 min (Figure 10B). With Ficoll, htt-
exon1(46Q) aggregation was quite different (Figure 10A). Large globular features 
appeared on the bilayer surface within the first 10 minutes. Rather than being 
associated with regions of a disrupted granular morphology, these large aggregates 
swelled in size, reaching heights as large as 20 nm above the bilayer surface and 
diameters on the order of 300-500 nm (Figure 10C). As these oligomers swelled, they 
occupied an increasing area of the bilayer. Additionally, holes spanning the entire 
bilayer appeared near these features within ~100 min, and these holes grew in size with 
time. 
 With PEG, regions of altered morphology formed on the bilayer within the first 10 
min, but unlike the control, these regions were not granular in appearance (Figure 10A). 
Rather, they displayed a smoother, raised morphology. The bilayer between these 
regions was also slightly rougher (0.33 ± 0.04 nm) than a typical TBLE bilayer (Figure 
10B). By ~30 min with PEG, a considerably large population of small oligomers appear 
on the bilayer, and the regions of altered morphology grow. By ~60 min, large 
aggregates start to appear on the surface. Holes exposing the mica substrate 
developed around these large aggregates as they grew in size. With time, these holes 
covered a larger area (microns in size). Meanwhile, the rest of the bilayer became 
rougher, with greater than 95% of the surface displaying some type of altered 
morphology within ~115 min (Figure 10D).  
3.4 Discussion 
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While toxicity has been attributed to numerous aggregate forms of htt, survival 
analysis of neurons expressing htt-exon1 correlated diffusely distributed htt within the 
cell to cell death. However, this diffuse htt can be comprised of various types of 
aggregate species. For example, a significant population of htt oligomers are detectable 
in mouse and cellular models of HD that occupy this diffuse fraction.62,63 However, htt 
fibrils are also present in the diffuse fraction, as detected by super-resolution 
microscopy.64 Here, using simple macromolecules, we demonstrated that a crowded 
environment modifies the heterogeneous distribution of htt-exon1 aggregates formed in 
vitro. While the crowded environment within the cytosol is much more complicated, 
these results suggest that crowding effects likely exert a strong influence on the 
composition of the diffuse htt fraction linked to toxicity. In addition, potential toxic 
mechanisms attributed to htt aggregation involves damaging membranes associated 
with a variety of organelles, including the ER, mitochondria, and nuclear 
envelope.10,35,40,65 Here, we demonstrate that crowding in the aqueous phase alters the 
interaction with htt at solid/liquid and solid/membrane interfaces. In particular, the 
interactions with lipid membranes was enhanced in by crowding in the aqueous phase, 
and this was highly dependent on the chosen crowder. This suggests that the crowded 
environment of the cytosol can play an important role in htt/membrane interactions that 
are associated with toxicity.  
There are several caveats in comparing the experiments on bilayers and mica. 
First, they used different models for htt aggregation, a synthetic N-terminal fragment of 
htt shorter than exon1 on mica and a full htt-exon1 protein on bilayers. Second, the 
crowder concentrations that were feasible to use varied, 100 mg/mL with mica and 25 
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mg/mL with bilayers. However, there are some interesting difference worth noting. On 
mica, the extent of aggregates observed was altered, but with dextran and ficoll, the 
morphology of aggregates, especially fibrils, appearing on mica was identical to those 
observed in control. With PEG, only small oligomers were observed and not in great 
enough quantity to make meaningful comparisons. However, on TBLE bilayers, the 
different crowders promoted unique aggregate morphologies. The morphology of 
aggregates of polyQ containing peptides formed in the presence of mica is 
predominately influenced by polyQ length, not flanking sequences.3,30 On the other 
hand, a variety of membrane properties, lipid composition, and flanking sequences 
within htt-exon1 influence the interaction of htt with bilayers.30,47,51,66 This dichotomy of 
aggregation behavior between the two surfaces with different macromolecular crowders 
suggests more than a simple mechanism associated with protein diffusion via crowded 
environments. Indeed, the lack of meaningful crowder concentration dependent 
difference in fibril elongation as measured by ThT assays (both with and without lipids) 
supports that htt diffusion is likely not significantly inhibited, as impeded diffusion is 
known to slow amyloid elongation.67,68 
All of the macromolecular crowders accelerated accumulation of htt-exon1(46Q) 
on TBLE bilayers within the first 1-2 h of exposure as measured the PDA assay and in 
situ AFM. This may be due to exclusion of htt-exon1(46Q) (and possibly membrane 
active aggregate species) from the solvent to the membrane interface. Localization and 
condensation of soluble proteins at lipid membrane interface is known to be sensitive to 
macromolecular crowding due to excluded volume effects.69,70 This excluded volume 
mechanism likely plays a larger role with dextran, as the htt-exon1(46Q) aggregates 
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and bilayer morphological changes resembled that observed in the absence of 
crowders. Beyond a simple excluded volume explanation, there appeared to be crowder 
specific interactions associated with ficoll and PEG with htt-exon1(46Q) as each 
promoted unique aggregate morphologies and changes in the bilayer. This may be due 
to local concentration effects that promote protein/protein and/or protein/lipid 
interactions at the membrane/liquid interface. Their enhanced local concentration 
promotes protein:lipid and protein:protein interactions, oligomerization and/or 
aggregation, while soluble proteins and crowders that do not associate with the 
membrane are largely excluded from the interface.71 In this regard, changing 
macromolecular crowders enhance accumulation of RBC‐modifying enzymes on cell 
surfaces up to 440‐fold.14  
Considering the unique aggregate morphologies observed on TBLE with the 
addition of ficoll and PEG, a question arises as to if these aggregates formed in solution 
before binding the membrane or if they developed from smaller species once bound to 
the membrane. The imaging frequency of the continuous in situ AFM imaging was not 
fast enough to settle this question; however, it offers some hints toward answering this 
question. With ficoll, the large aggregate appeared within the timeframe to take the first 
image after injection of htt-exon1(46Q). These aggregates could have formed in 
solution, as the ex situ AFM analysis revealed similar sized features forming in the 
presence of ficoll, with large portions of these aggregates being unique from the ficoll 
background at 50 and 200 mg/mL. This suggests that it is possible for these large 
features to have formed in solution prior to binding the surface. Once on the surface, 
these aggregates steadily grew in size and were associated with the development of 
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holes in the bilayer, suggesting they may accumulate membrane lipids as well. While 
some morphological features on bilayers were associated with relatively large 
aggregates in the presence of PEG, most of the morphological changes were 
associated with smaller feature or ubiquitously spread across the bilayer, suggesting 
that a large portion of the htt-exon1(46Q) interacting with the bilayer was not extensively 
aggregated. All of these experiments were pre-formed with the same lipid system. The 
observed differences in aggregation as a function of crowder suggest that htt-
exon1(46Q) localization to membrane interfaces is modified by the extent and type of 
crowding in the aqueous phase above the membrane surface.   
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4. Future Work and Concluding Remarks 
 The work presented in this dissertation was aimed at elucidating interactions of 
htt with surfaces, based on an electrostatic and lipid interface perspectives. To begin, 
an experimental system was established using mutations in Nt17 to htt phosphorylation. 
Once this system was validated, investigations were aimed at understanding the impact 
of phosphorylation on htt/lipid interactions with a variety of lipid systems. Understanding 
biophysical impact of phosphomimetic mutations on htt aggregation and lipid membrane 
activity may provide mechanistic detail regarding htt membrane association linked to 
toxicity. This was followed by a study aimed at elucidating how a crowded liquid phase 
influences htt aggregation at interfaces. A variety of macromolecular crowders were 
used, and each had a profound impact on aggregation at a mica/liquid interfaces and a 
membrane/liquid interface. The major goal of these studies individually was to 
understand fundamental aspects of htt aggregation, including charge and membrane 
interactions, in the presence of cellular and subcellular surfaces. The ultimate overall 
goal was to identify and expand upon potential targets for preventing mutant huntingtin 
aggregation; hopefully leading to more available, effective therapeutic and preventative 
treatments for HD. To further the work completed in this dissertation in context, 
implications for future studies are discussed. 
4.1 Impacts of PIP Lipids and Htt on Membranes 
Htt is associated with a variety of distinct membranes within neurons, each 
comprised of a distinct mix of lipid components. While htt can damage these different 
membranes, different aggregate species have been associated with specific organelles. 
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For example, oligomers have been implicated in mitochondrial membrane 
dysfunction;1,2 fibrils deform and damage the ER;3 and inclusion disrupt the nuclear 
envelope.4  Thus, it is important to understand how different lipid species influence 
htt/membrane interactions and aggregation.  Nt17 forms a membrane targeting AH, 
which facilities htt-exon1’s direct association with a variety of cellular and subcellular 
membranes via direct contact with phospholipids within the membrane.5–7 For example, 
mutant htt has increased binding affinity to numerous phospholipids,6,7 and mutant htt 
fragments can directly disrupt phospholipid bilayer integrity.7 Htt has displayed a high 
affinity for a small class of lipids called phosphatidylinositol phosphates (PIPs). Of the 
seven known PIPs, the low abundance (0.1% of total lipids) multivalent PIPs, PI(3,4)P2, 
PI(3,5)P2, PI(4,5)P2 and PI(3,4,5)P2, associate more strongly with htt.7–9 Due to the 
positive charge associated with the lysine residues in Nt17 which are integral to lipid 
binding;10 and the negative charge of PIPs, it is possible that lysines within Nt17 
underscore the high affinity of htt for PIP enriched membranes.  
Charged phospholipids, such as PIPs, interact with ions via Coulombic forces. 
Divalent cations and Li+ with POPC can change mechanics and shift membranes to a 
more gel-like state.11 It is then expected that cation induced clustering of PIP with Ca+2 
should rigidify the membrane by diminishing lateral diffusion, reduce leakage, and 
lessen the damage when htt is bound to the membrane. It is feasible to expect that 
changing the ionic strength could have an effect on how the membrane interacts with 
the htt protein. PIP2 forms clusters in vitro.12,13 Most models with PIP clustering use 
higher concentrations of divalent ions and PIP lipids greater than what is naturally 
present in the plasma membrane.12,14,15 To date, the effects of PIP clustering on htt 
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binding and aggregation are unknown. Calcium clearly plays a vital role in both PIP 
lipids and htt, but little evidence has been presented at physiological concentrations. 
This clustering would have additional consequences in downstream applications 
of htt, for example, PIP enriched membranes play a key regulatory role in AKT-
mediated phosphorylation of htt.7–9 While the interaction of primary PIPs, such as 
PI(4,5)P2, with htt has been analyzed in the literature16, the structural changes resulting 
from interaction of secondary multivalent PIPs PI(3,4)P2 and PI(3,4,5)P3 with htt has not 
been explored in depth. Most studies focus toward animal models and immune or 
cytotoxicity evidence that can be related back to the kinases and pathways,17,18 with 
little information on the actual binding event that initiates these processes. A model for 
htt recruitment to the plasma membrane by PIPs during growth factor signaling shows 
that the type III kinase uses PI(4)P2 and PI(4,5)P2 as substrates to create PI(3,4)P2 and 
PI(3,4,5)P3 at the membrane surface.16 Experiments with lipid overlay indicate that htt 
binds multivalent PIPs which is consistent with an electrostatic mode of association.8 
PIPs provide a high affinity binding site on the inner cytosolic membrane surface for 
proteins like AKT and htt.9 Htt is a substrate for AKT and phosphorylation of htt by AKT 
is crucial for neuroprotective effects but is altered by mutant htt.19 Due to PIPs clustering 
ability with Ca+2, it appears that mutant htt and AKT could accumulate along with GSKβ 
to activate cell death pathways with mutant htt.7  
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Figure 4.1: Proposed interaction of Nt17 association with PIP and PIP/Ca+2 vesicles. The 
binding of Nt17 to PIP/Ca+2 clusters on a lipid membrane (left) can expect to have a stronger 
response than the binding of Nt17 to PIP enhanced lipid membranes (right). This is due to 
increased electrostatic interactions, however both proposed interactions lead to downstream 
therapeutic pathways focused on reduced toxicity.   
 
Administration of PIPs or altering PIP kinases as a therapeutic target in animal 
models have included direct application to the brain, altering embryonic or similar 
developing cells in animal models16 or non-physiological conditions,20 which is 
unrealistic for future treatment of HD. Recent efforts have shown that increasing the 
levels of PIP decreases the amount of protein aggregation associated with several 
neurodegenerative diseases,16 but little is known about the mechanism.  Similar to the 
approach used in Chapter 2, mechanisms underscoring the high affinity of htt for PIP 
and the potential role of lysine residues can be determined. For example, lysine 
residues in Nt17 are often acetylated, altering their charge and modifying htt-exon1’s 
ability to associate with lipid membranes. Acetylation mimicking mutations in Nt17 can 
be employed to investigate their role in binding with membranes enriched with 
physiologically relevant amounts of PIP. By targeting these lipids, Nt17, and optimizing 
physiologically similar conditions to study these underlying concepts, clear mechanisms 
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will be associated with htt aggregation that can potentially lead to the rationale design of 
strategies to target htt/PIP binding events for therapeutic purposes. Additional 
significance is providing extended fundamental knowledge of the membrane mediated 
htt aggregation.  
4.2 Exploration of PTM Crosstalk, Charged and Complex Lipid Systems, and 
Organelles with Htt 
As mentioned in Chapter 2, certain PTMs are crucial modulators of htt 
aggregation and toxicity.21,22 The high number of overall PTMs within Nt17 implies that 
these modifications are essential to the functions of htt, in health, and disease.23 In 
particular, Nt17 contains numerous residues for two charge altering PTMs, acetylation 
and phosphorylation.24 The juxtaposition of the phosphorylation and acetylation PTMs 
induces crosstalk between the residues, establishing a molecular switch for modifying 
the dynamics of htt aggregation and function.23 Clarifying the regulatory molecular 
mechanisms of these PTMs and the consequences of such modifications, is crucial for 
elucidating the basis of many htt functions within HD. For example, the acetylation of K6 
residues in htt reverse aggregation inhibitory effects of T3 phosphorylation, due to the 
close proximity and stabilizing role of K6 in Nt17 helix formation.25 However, more 
detailed studies are necessary to determine the various mechanisms in which PTMs 
crosstalk, and their downstream effects on htt aggregation and lipid binding in vivo.  
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Figure 4.2: Comparison of phosphorylation and acetylation PTM sites on Nt17. Overhead 
view of the barrel of the Nt17 α-helix, showing hydrophobicity of each residue (as indicated by 
legend) and all reported PTMs. The phosphorylation PTM sites (green) of T3, S13 and S16 are 
in close proximity to the acetylation PTM sites (purple) of K9 and K6. The center line is 
representative of the membrane of cells, and K6, K15 and S13 are all noticeably closer to the 
membrane. This suggests that selectively altering these PTMs together should have even 
stronger effects on lipid binding.  Adapted in part with permission from Arndt, J.R. et al. The 
Emerging Role of the First 17 Amino Acids of Huntingtin in Huntington’s Disease. Copyright 
2015 Biomolecular Concepts. 
 
There are also implications that membrane affinity influenced by phosphorylated 
htt is sensitized to complex, defect riddled membranes. In further expansion of the ideas 
outlined above, increased modification of electrostatic interactions using double and 
triple site phosphomimics and increasing cross talk via combinations of acetylation and 
phosphorylation PTMs mimics in Nt17, both serve as potential outlets for targeting 
specific cellular and subcellular membranes of differing composition. Additionally, 
phosphorylation and acetylation in tandem modify the localization of huntingtin 
throughout cells.26–31 This suggests that including the study of complex membranes 
found on cellular organelles, such as mitochondria and endoplasmic reticulum (ER), 
would be suitable future directions to the expansion of this study.  
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Another hallmark of HD is altered mitochondrial morphology, with various 
irregularities in dissimilar cell types.32 Modified mitochondrial structures correspond to 
mitochondrial dysfunction in HD cells, established by numerous factors including 
decreased electron transport chain activity.32,33 In particular, neurons are distinguished 
by amplified mitochondrial fragmentation.34–37 Additionally, ER stress progresses in 
many neurodegenerative diseases including HD,32,38,39 and it is a key influence in the 
deterioration of cells.34,40–42 As misfolded proteins intermingle and aggregate in the cell, 
toxic species arise that cause ER stress and disrupt normal cellular function.34 With a 
cytosolic protein such as htt, intrusion of oligomers with ER-associated degradation 
(ERAD) mechanisms has been elucidated in HD to be an influential process of initiating 
ER stress.43,44 Fundamental concepts elucidated in Chapter 2 could be further applied 
to see if increasing electrostatic interactions through PTMs leads to protective effects in 
downstream aggregation in the presence of these complex organelles; or determine if 
there is increased selective affinity of various PTMs within Nt17 for these membranes. 
Other charged, pure lipid systems such as the anionic POPS or DOPG lipids, or 
mixed model lipid systems could also be studied to fine tune the effects of particular 
lipids found within the complex membranes of cells. Insertion depths of PTM residues 
on various membranes could be monitored in an attempt to shed light on particular 
binding mechanisms that occur, to further elucidate pre-existing findings associated with 
PTMs, including crosstalk between different PTMs. PTMs likely play a prominent role in 
htt’s normal function and modify mutant htt toxicity. Understanding the complex relation 
between PTMs, lipid association, aggregation, and toxicity would hopefully lead to novel 
therapeutic strategies targeting Nt17.  
Chapter 4 | 103  
 
4.3 Liquid/liquid Phase Separations, Stress Granules, and Htt Aggregation 
Mechanisms In Vivo. 
In Chapter 3, macromolecular crowding impacted the formation of htt aggregate 
species and aggregation at interfaces. In particular, large htt granules were observed 
under some crowding conditions that morphologically were similar to stress granules 
(SGs) found in cellular environments. Traditionally, isolation of molecules into 
organelles is attained by encompassing the organelles with lipid membranes.45 Micro-
niches within the cell that demonstrate liquid-like qualities, including SGs, nucleoli, germ 
granules and paraspeckles, have been collectively labelled as biomolecular 
condensates46 or membraneless organelles (MLOs).47–49 MLOs are intracellular 
assemblies that are key to numerous fundamental mechanisms within in cell, including 
protein transport.50,51 Association of MLOs occurs through a process termed liquid-liquid 
phase separation (LLPS), a metastable de-mixing process of proteins facilitated by 
temporary multivalent interactions.52–56 Several diverse interactions influence LLPS that 
in turn, promotes formation of explicit MLOs with varying functions, as demonstrated by 
SGs and countless others.46,49,50 Solutions of macromolecules that endure LLPS 
condense into a dense phase that is similar to liquid droplets, coalescing with a dilute 
phase.57 The fundamental driving force of this process being the switch of 
macromolecule/water interactions for energetically favorable water/water interactions 
and macromolecule/macromolecule interactions.57 The propensity of a solution to 
engage in LLPS depends on numerous factors, including concentration and identities of 
the macromolecules involved, temperature, salt concentration, co-solutes, and volume 
exclusion.47,50,57  
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The cytosol in particular contains high levels of disordered proteins that are not 
entirely neutral.58 The formation of macroscopic puncta (or granules/bodies) in the cell 
from these proteins adds an additional level of complexity.47 The cytoplasm and 
nucleoplasm of a multitude of cells are interspersed with condensates, that are 
disconnected from the adjacent fluid, which are dynamically established and liquefied 
over time.47,58,59 SGs are particularly relevant to neurodegenerative diseases, as 
functions associated with SG response have mutations associated with motor neuron 
diseases.45 Therapeutic tactics intended for hindering SG accretion have shown to 
reduce disease advancement in animal models of neurodegenerative diseases.45,60,61  
 
Figure 4.3: Location of stress granules (SGs). While found in numerous cellular 
environments, SGs can be found in close proximity to the nucleus of motor neurons. This is 
significant as htt also accumulates in and around the nuclei of neurons, leading to the 
assumption that SGs interact with and possibly affect htt aggregation. Created in part with 
BioRender.com 
 
Additionally, there is significant overlap among proteins that undergo LLPs and 
those that aggregate in neurodegenerative diseases.50,62–64 Proteins containing 
intrinsically disordered regions (IDRs) stimulate LLPS yet come at the cost of being 
highly aggregation prone, suggesting that this overlap might be connected in disease 
pathogenesis.50,62–65 In vitro models of purified proteins and synthetic crowding agents 
Chapter 4 | 105  
 
have been explored to determine the effect of crowding on MLOs,47 though research is 
lacking in this area with htt. In vitro studies are essential to providing insight to the 
functions and qualities of MLOs on biomolecular processes,46,49,52–54,65–73 though the 
effect of macromolecular crowding on LLPS is rarely discussed in detail despite them 
being a common addition in these studies.47 Thus, macromolecular crowding influences 
phase separation in mixtures that would not otherwise demonstrate crowder-mediated 
LLPS in living cells.47 
 
Figure 4.4: Lipid/Lipid phase separation (LLPS) of htt. Normal htt (blue, top left and right) in 
cellular conditions can undergo a reversible, transitional process in which aggregates (pink, top 
right) begin to form, but not in enough severity to form fibrillar structures. This dense collection 
of proteins and macromolecules (represented by green, orange and purple dots) then begin to 
condense into a liquid-like phase within the surrounding fluid. From here, in cases of expanded 
polyQ, the liquid phase can progress into a solid-like phase. Alternatively, this normal htt can 
undergo a similar process, where aggregates form and condense into solid-like structures such 
as fibrils (red, bottom). In this alternative pathway, the presence of expanded polyQ regions 
within htt can promote a direct transition to these solid-like structures. Created in part with 
BioRender.com 
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Current understanding in the formation of MLOs such as SGs within cells, raises 
another possible aggregation mechanism for htt, as the aggregation mechanism of htt in 
vivo is still unclear.74 Htt-exon1-fluorescent fusion proteins frequently accumulate into 
micron-sized aggregates, orders of magnitude larger than the deposits frequently 
analyzed in vitro.74 Ultrastructural studies allude that these aggregates contain granular 
and/or fibrillar substructures.75–77 Solidification of protein condensates such as SGs has 
also been associated to other neurodegenerative diseases such as PD and AD, in 
which they lose their liquid-like properties and begin forming amyloid fibrils.78,79 
Investigation of the electrostatic interactions which influence multiple factors involved in 
the thermodynamic mixing of LLPS, could prove insightful to determining the threshold 
at which some MLOs become too dense and begin to form condensates that affect 
normal cellular function. In addition to defects, Nt17 has a distinct relationship with the 
curvature of surfaces.80 The presence of multiple complex lipid membranes and the 
surfaces of MLOs indicates exploring details about the fluidity, composition and 
curvature of these surface components could prove useful in elucidating in vivo 
mechanisms of htt aggregation. Together, these concepts provide motivation to 
determine how macromolecular crowding induces LLPS in htt and if that in turn, furthers 
the severity of aggregation.  
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Appendix: Huntingtin Protein Purification and Experimentation with 




Traditional undergraduate biochemical laboratory curricula are confronted with 
multitudinous challenges in improving student learning outcomes due to limitations with 
time, increased student enrollment, and high-cost laboratory resources. However, with 
the advent of cost-effective instrumentation and incorporation of creative approaches to 
circumvent inflexible undergraduate schedules, it is now possible to overcome these 
challenges. Thus, we have designed an interdisciplinary, medically relevant laboratory 
experiment intended to provide undergraduate students with enhanced pedagogical 
training through guided- and independent-based inquiry. This experiment seeks to 
mediate limitations common to traditional biochemical experimentation using high-level 
instrumentation in tandem with graduate-level student engagement.    
A1. Introduction 
Science, technology, engineering, and mathematic (STEM) educational 
programs have seen an increase in majors, including subdivisions such as 
biochemistry, bioinorganic chemistry, bioorganic chemistry, biophysical chemistry, 
agriculture, and food science.1–3 Rigorous coursework and laboratories, along with 
undergraduate research experiences, are essential for STEM majors; however, not all 
students can participate in undergraduate research. Thus, students do not obtain the 
crucial training or engaged learning needed for upper-level educational programs or 
STEM careers. The need for undergraduate laboratory experiments that provide 
relevant graduate-level experiences is becoming increasingly necessary. Available 
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biochemistry laboratories have seen very little graduate-level experimentation because 
laboratory design tends to follow an expository style format where students acquire very 
limited and superficial knowledge through passive completion of a “cookbook” protocol.4 
This is due in part because most undergraduate scientific laboratory experiments have 
limitations with both equipment and time.4–8 
Typical biochemistry laboratory courses consist of a two-semester model where 
the first semester focuses on acquiring basic biochemical skills, including proper 
pipetting techniques, preparation of solutions and buffers, and familiarization with basic 
instrumentation such as electrophoresis, colorimetric ultraviolet-visible spectroscopy 
and size exclusion chromatography. The second semester centers on higher-level 
biochemical techniques for the analysis of biological species and processes, including 
cell growth and protein expression. Emphasis is applied on providing knowledge of 
biochemical techniques from a practical perspective and developing critical thinking 
skills to prepare graduates. This model, although established and convenient, is 
problematic in that the time constraints of most undergraduate biochemistry laboratories 
allow for unoriginal applications that do not facilitate intellectual growth through critical 
thinking skills development that is provided via research-based experiences. Thus, 
these educational labs lack the veracities associated with higher level biochemical 
employment or education. The idea of straying from a traditional learning format by 
changing experimentation to a more research-based approach has been well 
received.4,9–11 
Cost effective availability of biological instrumentation has made it possible to 
add a more advanced component to biochemical laboratory experiments. Refrigerated 
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centrifuges, microplate reader spectrophotometers, digital incubators, and specialized 
chromatography columns are now available and could provide valuable experiences 
when transitioning to graduate level education or industry. For example, protein 
expression and purification in undergraduate laboratories has been successful with 
diverse recombinant proteins in Escherichia Coli (E. Coli). Opportunities for 
experimental modifications exist within the protein expression and purification 
processes9–12 and have been demonstrated with versatility in chromatography.11 
Despite these modifications, without a change in the style of learning, students will not 
be able to reap the benefits of a graduate level experience.  
We have designed an undergraduate biochemistry laboratory experiment 
involving the huntingtin protein (htt) that incorporates guided and inquiry-based 
experimentation with emphasis on instrumentation and graduate-level participation. This 
experiment models other independent graduate level work being conducted but has 
been adapted to accommodate the inflexible undergraduate timeline. The experiment 
focuses on immersion into the graduate school environment coupled with the use of 
advanced instrumentation, which will provide excellent undergraduate learning 
opportunities that can be expanded and are markedly useful when moving forward in a 
scientific career. Further, interest amongst the students will persist and will encourage 
independent research on the topic by using a popular and medically relevant protein, in 
contrast to traditional enzymatic based biochemistry experiments.9,12–14  
A2. Background 
  The primary genetic cause of several neurodegenerative diseases is the 
expansion of trinucleotide repeats to a greater number than what occurs in the naturally 
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occurring stable gene.15–17 Trinucleotide repeat disorders (TRDs) result from an 
abnormal expansion of repetitive codon sequences within a gene and primarily affect 
the nervous system. A subclassification of TRDs consist of a group of 10 disorders in 
which the codon CAG, which encodes for the amino acid glutamine (Q), is repeated and 
results in an expanded polyglutamine (polyQ) tract within the translated protein. This 
subset of TRDs is commonly referred to as CAG repeat disorders or polyQ diseases. 
The 10 identified CAG repeat disorders include Huntington’s Disease (HD),18 
dentatorubal-pallidoluysian atrophy (DRPLA or Haw River Syndrome),19 the 
spinocerebellar ataxias, type 1 (SCA-1), type 2 (SCA-2), type 3 (SCA-3 or Machado-
Joseph disease), type 6 (SCA-6), type 7 (SCA-7), type 12 (SCA-12), type 17 (SCA-
17)20–26 and spinobulbar muscular atrophy (SBMA or Kennedy’s disease).27  
Generally, expansion of polyQ beyond a critical threshold is required for disease. 
Onset of symptoms and age are strongly correlated to polyQ length. In HD, polyQ 
repeat lengths of approximately 35 in htt are considered the critical threshold, with 
increased severity as the repeat length increases.18,28–31 A key hallmark of the 
aforementioned expanded polyQ diseases is the accumulation of abnormal proteins into 
proteinaceous deposits. These deposits are predominately comprised of aggregate 
species termed amyloid that are defined by a fibrillar morphology and a cross β-sheet 
structure. In particular, polyQ expansion promotes htt’s aggregation into fibrils.32 
However, multiple aggregation pathways exist, involving a variety of other aggregate 
species, including oligomers, annular structures, and amorphous aggregates.15,32,33 
Within the literature, htt oligomers34–36 and fibrils37,38 have been classified as toxic 
entities.  
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The six-week experiment outlined demonstrates the E. Coli based expression 
and purification of a GST-htt-exon1 fusion protein with a disease length polyQ domain. 
Cleaving the GST induces aggregation that can be tracked kinetically by a 
fluorescence-based aggregation assay. Students used this assay to determine the 
impact of variety of factors on htt aggregation. Specifically, to test if mimicking the 
crowded environment of the cytosol with macromolecular crowders impacted htt 
aggregation. Emphasis was placed on facilitation of advanced critical thinking when 
designing the independent experiment, graduate level presentations, and manuscript 
writing. Collaboration and feedback was provided throughout the weekly experiments, 
including personalized feedback during preliminary oral presentations. 
A3. Overview of Experiment 
In this six-week experiment, students completed the weekly laboratory work in a 
large group, 10-15 students per laboratory session, with a total of 22-30 students 
completing the experiment each semester. Smaller sub-groups were generated and 
rotated based on weekly tasks (Table A1), which allowed for participation in all the 
various components of the experimental procedure.  
Similar to graduate level education or STEM careers, students completed both 
oral and written presentations of their scientific findings. Students were asked to focus 
on providing a professional presentation that could be delivered at a scientific 
conference. They were also expected to provide weekly written records along with a 
final manuscript that replicated the publication style of a peer-reviewed scientific journal; 
student manuscripts were in the style of the American Chemical Society (ACS) 
Biochemistry journal.   
Appendix | 118  
 
Week 1: Several inoculations of E. coli with the vector to express a GST-htt-exon1 
fusion protein were generated to demonstrate various stages of protein expression. The 
starting times of these inoculations were offset to allow students to participate in the 
entire process, allowing the entire process to fit within a typical three-hour laboratory 
period.  
Students alternate between stations to gain experience with each step of E.coli growth 
and protein expression, including the preparation of growth media and autoclave 
sterilization techniques. Students set up an overnight inoculation of a strain of E. Coli 
containing the plasmid for the GST-htt fusion protein, prepare fresh media with 
ampicillin, and continue through the protocol with a previously prepared overnight 
culture. Protein expression is induced using isopropyl-β-D-thiogalactoside (IPTG) and 
cell harvesting is demonstrated; however, protein expression and cell harvesting of the 
offset inoculation was completed outside of the lab period.  
Week 2: Alternating stations, students prepare buffers needed for purification, suspend 
cell pellets, and perform protein extraction by lysing cells with lysozyme and sonication. 
Using small-scale glutathione (GST) affinity centrifugation columns, each student 
participates in the purification process. Additionally, assays to measure protein 
concentration and dialysis techniques are demonstrated.  
Week 3: Use of a microplate reader spectrophotometer and plate organization is 
discussed to prepare students for the following week’s experiment (Week 4). Students 
then participate in an excel workshop that focuses on scientific data analysis, which 
students will complete independently during Week 4, and include in both their oral 
presentation and manuscript.  
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Week 4: Students complete the required aggregation assays without significant 
guidance from the instructor; minimal assistance is key to ensure students are 
collaborating and developing metacognition skills. Although the impact of 
macromolecular crowding on htt aggregation was examined here, there are several 
experimental adaptations available.   
Week 5/6: Students combine hypotheses, testing procedures, observations, results and 
conclusions into a scientific manuscript that replicates the publication style of a 
biochemical scientific journal. Students also presented their findings as if at a scientific 
conference, allowing early opportunities for students to receive positive feedback on 
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Table A1: Devised Solutions to Traditional Experimental Setbacks  
Weekly Breakdown Traditional 
Setback  
Solution 
Week 1: Protein Expression in E. coli  Instrument 
availability, time 
management 
E. coli are staggered at various stages of growth for 
protein expression.  
Students are distributed into groups to gain 
experience with all aspects of these processes. 
Week 2: Protein Purification Instrument 
availability, time 
management 
Small scale purification methods enable many 
students to actively participate in protein purification. 





The Excel workshop focuses on scientific data 
analysis, and its presentation in both oral and 
manuscript forms.  
Students utilize mock data with open discussions 
encouraged. 







and assessment  
Students design an experiment testing various 
conditions based on previously learned techniques, 
specifically with macromolecular crowders.  
Minimal supervision is provided as students are 
responsible for experimental setup and execution. 
Weeks 5 & 6: Professional Oral 









Students drafted and presented their analyzed data 
over a two-week period. Emphasis was placed on 
providing presentations that could be delivered at 
professional scientific conferences.  
Weekly notebooks were combined into a scientific 




Bradford reagent, hydrochloric acid (HCl), and sodium hydroxide (NaOH) can 
cause burns and are corrosive. Sodium phosphates can irritate the nose and throat 
when inhaled and could result in respiratory difficulties; sodium phosphates can also 
pass through the skin and irritate the eyes. Glycerol can be harmful if swallowed. 
Ampicillin may cause allergic reactions. Trizma base, isopropyl-β-D-
thiogalactoside (IPTG), ethylenediaminetetraacetic acid (EDTA), yeast and tryptone 
may cause skin and eye irritation and may be harmful if swallowed or inhaled. Thioflavin 
T is corrosive and can cause burns, serious eye irritation and targets respiratory 
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system. Huntington protein and all related waste is classified as Biological Safety Level 
-1 (BSL-1) and should be treated with a 10% bleach solution and autoclaved prior to 
disposal.  
A5. Results and Discussion 
This experiment can be utilized in a biochemistry or biochemistry-related 
laboratory course where students have been introduced to protein and kinetic topics in 
previous coursework. The experiment requires four three-hour laboratory sessions with 
two additional three-hour sessions for oral presentations as outlined above.  
Typical student results obtained during the initial three laboratory sessions 
(Weeks 1-3) included an average absorbance value between 0.500-0.700 at 600 nm for 
the optical density of the larger batch broth cultures. Following purification during Week 
2 of experimentation, students generally obtained approximately 10-12 mL of 0.2-0.4 
mg/mL of htt. If the concentration of the protein fractions alone was greater than 20 µM, 
neat buffer was used to dilute the sample until the concentration was below 20 µM. This 
was to ensure minimal htt loss due to premature aggregation during dialysis and provide 
a sufficient quantity of diluted htt to generate mock data. During Week 3, students 
completed an excel data analysis using mock data. In the final week of experimentation 
(Week 4), students determined the concentration of htt after dialysis with typical 
concentrations ranging from 2-10 µM depending on the success of the purification. 
Students also developed a plate layout for the three macromolecular crowders used, 
Dextran, Ficoll, and polyethylene glycol (PEG). A final concentration of each 
macromolecular crowder at either 100 mg/mL or 50 mg/mL in 100 µL (the volume in 
each well) was achieved while still accounting for the final target concentration of htt (10 
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µM). Crowder volumes for these target concentrations were determined from a dilution 
scheme by the students using previously prepared stocks. 
A Thioflavin T (ThT) assay was used to assess fibril formation of htt incubated 
with the three macromolecular crowders. Students were assigned final concentrations of 
either 100 mg/ml or 50 mg/ml of the macromolecular crowders with the assay being 
completed in triplicate. Figure A1 demonstrates student obtained ThT assay data of htt 
in the presence and absence of crowders. Students assessed trends in fibril formation 
by the location of each signal in relation to htt alone. A signal higher than the htt control 
(no crowders) indicated enhancement of fibril formation. Polyethylene glycol (PEG) at 
both concentrations produced a diminished signal relative to control, indicating inhibition 
of fibril formation.  
 
 
Figure A1: Representation of student obtained data during experiment. Student data with 
10 µM htt in the presence and absence of Ficoll, Dextran and PEG at (A) 50 mg/mL and (C) 100 
mg/mL. Quantification of the maximum ThT fluorescent signal observed for Ficoll, Dextran and 
PEG at (B) 50 mg/mL and (D) 100 mg/mL with respect to htt alone is present. Error bars 
represent SEM with * corresponding to p<0.01 and ** corresponds to p<0.05. 
 
In addition to traditional weekly laboratory notebooks, students were assessed by 
the oral presentations and final manuscripts. For the laboratory notebooks, sections 
such as the introduction to the experiment, experimental objectives, materials and 
methods, results and discussion, conclusion and laboratory questions were requested 
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each week. The laboratory questions as well as the experiment objectives section in the 
written pre-laboratory assignment were key pieces for evaluating basic knowledge of 
the pedagogical goals prior to completing the weekly experiments. Post-laboratory 
results, discussion, and conclusion sections judged the level the students understood 
the weekly experimental goals, identifying what information would be relevant to 
continue for the following week’s task, and demonstrated if students were thinking 
critically about what to include for their manuscript. Students scored exceptionally well 
for the laboratory notebooks, with an average grade of 91%. High scores are indicative 
that the pedagogical goals of each week were effectively communicated and achieved.  
The oral presentations following the completion of week #4 were used as a 
measure of assessment for the combination of the student’s overall understanding of 
the experiment, professional speaking, and communication skills. Prior to the 
presentations, students were encouraged to follow guidelines with regards to the 
background information, experimental procedures, results, and conclusions. It was 
stressed that focus should be placed on the results, what they mean and why they were 
significant to the broader scientific community. Current literature and proper 
identification of the overall goal were also critically evaluated. Proper referencing, slide 
aesthetics and knowledge during the question sessions from peers and instructors were 
also provided as guidelines and judged to help create an immersive, conference-style 
setting. Again, students scored well for the oral presentations, with an average grade of 
84%. For most of the students, this style of evaluation and experience was their first 
opportunity within the program, adding a much-needed component for an upper level 
undergraduate course. 
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Upon completion of the oral presentations, students submit a manuscript of their 
results written in Biochemistry format. A template for the manuscript is provided, and 
students are expected to use the information from their laboratory notebooks and 
feedback from their presentations. Students were presented with a list of appropriate 
sections, suggestions of what to include in each section, and were encouraged to read 
literature in similar areas of study and format. Deeper understanding of the ThT results, 
htt aggregation and fibril structure, and relation of the experiment to real world situations 
were expected to be elucidated. Determining if results were significant through statistics 
and areas for improvement were also emphasized strongly. The average grade for the 
manuscripts was 77%, again suggestive that students were retaining the knowledge 
learned and effectively using critical thinking skills to structure the manuscript. This was 
the first experience with writing a publication-type document for students within the 
major, so a learning curve was to be expected.  
Overall, student evaluations revealed that 79% of students enjoyed the 
experiment. Students responses also indicated increased satisfaction with the hands-on 
nature of the experiment, use of multiple lab spaces, newly gained knowledge of the 
preparation required for larger-scale experimentation, and group collaboration. Students 
also indicated the significant usefulness of learning upper-level techniques and 
instrumentation, including spin GST-affinity based column chromatography, and LC 
GST-affinity based column chromatography, large scale recombinant protein expression 
and cell lysis. Specific student comments encompassing the entirety of the experiment 
included “we were able to take part in all the steps without using multiple lab days”, “the 
excel lab taught functions that were useful for data analysis and helpful for future 
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classes”, “that we actually learned how to generate complicated graphs we see in 
papers” and “we finally had a coursework lab that incorporates techniques used in real 
graduate level labs. It gave the lab group a sense of autonomy and responsibility in 
dividing and conquering work.” 
Conversation and positive encouragement were fostered throughout each week 
of the experiment as students encounter common experimental issues or struggle to 
envision the experimental goals. This is especially critical for students who have had no 
exposure to undergraduate research or have been conditioned for traditional “cookbook” 
protocols that are expected to work with little error. Additionally, early communication 
between student and instructor helps to bridge the guided laboratory structure to the 
desired independent inquiry-based format. Through these activities’ students gained 
important knowledge in data analysis and the use of sophisticated scientific 
instrumentation, acquired insight into upper-level biochemical experimentation, and 
have a better understanding of real-world issues currently faced in biochemistry and 
biochemistry related fields.   
A6. Summary 
When compared to traditional biochemical experiments involving protein 
expression and purification, this experiment allowed for an atypical, interesting, and 
impactful protein to impart some new life into a curriculum that is steadily becoming 
stale and less relevant for students seeking STEM careers. Additionally, these modified 
protein expression, purification, and experimental protocols successfully demonstrated 
their innovative use by circumventing the time-constraints typically plaguing an 
undergraduate laboratory course along with allowing for cost effective use of equipment 
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and materials. Experimental focus on improving communication and critical thinking 
skills are both useful and necessary for career paths in STEM. Students also have a 
better understanding of a biologically relevant protein and its role in HD, along with how 
the efficacy of potential treatments are evaluated in disease prevention.   
A7. References 
(1)  Biochemists and Biophysicists : Occupational Outlook Handbook: : U.S. Bureau of 
Labor Statistics. 
(2)  (2016, March 20) Stem Majors on the Rise as Humanities Decline Across the 
Country. Emsi. 
(3) Martin-Hansen, L. (2018) Examining ways to meaningfully support students in 
STEM. Intl J STEM Educ 5, 53. 
(4) Domin, D. S. (1999) A Review of Laboratory Instruction Styles. J Chem Educ 76, 
543. 
(5) Mordacq, J., Drane, D., Swarat, S., and Lo, S. (2017) Research and Teaching: 
Development of Course-Based Undergraduate Research Experiences Using a Design-
Based Approach. J Coll Sci Teach 46. 
(6) Weaver, G. C., Russell, C. B., and Wink, D. J. (2008) Inquiry-based and research-
based laboratory pedagogies in undergraduate science. Nat Chem Biol 4, 577–580. 
(7) Brew, A., and Saunders, C. (2020) Making sense of research-based learning in 
teacher education. Teach Teach Educ 87, 102935. 
(8) Sales, J., Comeau, D., Liddle, K., and Khanna, N. (2006) Bridging the Gap: A 
Research-Based Approach for Teaching Interdisciplinary. Sociology. 
(9) Craig, P. A. (1999) A Project-Oriented Biochemistry Laboratory Course, J Chem 
Educ 76, 8, 1130. 
(10) Maza, J. C., Villa, J. K., Landino, L. M., and Young, D. D. (2016) Utilizing Unnatural 
Amino Acids To Illustrate Protein Structure− Function Relationships: An Experiment 
Designed for an Undergraduate Biochemistry Laboratory. J Chem Educ, 5. 
(11) Peterson, M. J., Snyder, W. K., Westerman, S., and McFarland, B. J. (2011) 
Preparative Protein Production from Inclusion Bodies and Crystallization: A Seven-
Week Biochemistry Sequence. J Chem Educ, 4. 
(12) MacDonald, G. (2008) Teaching Protein Purification and Characterization 
Techniques. A Student-Initiated, Project-Oriented Biochemistry Laboratory Course. J 
Chem Educ 85, 1250. 
(13) Deal, S. T., and Hurst, M. O. (1997) Utilizing Isolation, Purification, and 
Characterization of Enzymes as Project-Oriented Labs for Undergraduate Biochemistry. 
J Chem Educ 74, 241. 
(14) Markwell, J. (1993) Focusing on a single enzyme: An undergraduate biochemistry 
laboratory course supported by the NSF. J Chem Educ 70, 1018. 
(15) Adegbuyiro, A., Sedighi, F., Pilkington, A. W., Groover, S., and Legleiter, J. (2017) 
Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease. 
Biochemistry 56, 1199–1217. 
Appendix | 127  
 
(16) La Spada, A. R., and Taylor, J. P. (2010) Repeat expansion disease: Progress and 
puzzles in disease pathogenesis. Nat Rev Genet 11, 247–258. 
(17) Budworth, H., and McMurray, C. T. (2013) A Brief History of Triplet Repeat 
Diseases. Methods Mol Biol 1010, 3–17. 
(18) Macdonald, M. (1993) A novel gene containing a trinucleotide repeat that is 
expanded and unstable on Huntington’s disease chromosomes. Cell 72, 971–983. 
(19) Miyashita, T., Nagao, K., Ohmi, K., Yanagisawa, H., Okamura-Oho, Y., and 
Yamada, M. (1998) Intracellular Aggregate Formation of Dentatorubral-Pallidoluysian 
Atrophy (DRPLA) Protein with the Extended Polyglutamine. Biochem Biophys Res Co 
249, 96–102. 
(20) Orr, H. T., Chung, M., Banfi, S., Kwiatkowski, T. J., Servadio, A., Beaudet, A. L., 
McCall, A. E., Duvick, L. A., Ranum, L. P. W., and Zoghbi, H. Y. (1993) Expansion of an 
unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 4, 221–
226. 
(21) Kawaguchi, Y., Okamoto, T., Taniwaki, M., Aizawa, M., Inoue, M., Katayama, S., 
Kawakami, H., Nakamura, S., Nishimura, M., Akiguchi, I., Kimura, J., Narumiya, S., and 
Kakizuka, A. (1994) CAG expansions in a novel gene for Machado-Joseph disease at 
chromosome 14q32.1. Nat Genet 8, 221–228. 
(22) Moriarty, A., Cook, A., Hunt, H., Adams, M. E., Cipolotti, L., and Giunti, P. (2016) A 
longitudinal investigation into cognition and disease progression in spinocerebellar 
ataxia types 1, 2, 3, 6, and 7. Orphanet J Rare Dis 11. 
(23) Bauer, P., Kraus, J., Matoska, V., Brouckova, M., Zumrova, A., and Goetz, P. 
(2004) Large de novo expansion of CAG repeats in patient with sporadic 
spinocerebellar ataxia type 7. J Neurol 251. 
(24) Nakamura, K. (2001) SCA17, a novel autosomal dominant cerebellar ataxia caused 
by an expanded polyglutamine in TATA-binding protein. Hum Molec Genet 10, 1441–
1448. 
(25) Zhuchenko, O., Bailey, J., Bonnen, P., Ashizawa, T., Stockton, D. W., Amos, C., 
Dobyns, W. B., Subramony, S. H., and Zoghbi, H. Y. (1997) Autosomal dominant 
cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the a 1A-
voltage-dependent calcium channel Nat Genet 15, 62-9. 
(26) Choubtum, L., Witoonpanich, P., Hanchaiphiboolkul, S., Bhidayasiri, R., 
Jitkritsadakul, O., Pongpakdee, S., Wetchaphanphesat, S., Boonkongchuen, P., and 
Pulkes, T. (2015) Analysis of SCA8, SCA10, SCA12, SCA17 and SCA19 in patients 
with unknown spinocerebellar ataxia: a Thai multicentre study. BMC Neurol 15. 
(27) Katsuno, M., Adachi, H., Doyu, M., Minamiyama, M., Sang, C., Kobayashi, Y., 
Inukai, A., and Sobue, G. (2003) Leuprorelin rescues polyglutamine-dependent 
phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat 
Med 9, 768–773. 
(28) Tobin, A. J., and Signer, E. R. (2000) Huntington’s disease: the challenge for cell 
biologists. Trends in Cell Biology 10, 531–536. 
(29) Snell, R. G., MacMillan, J. C., Cheadle, J. P., Fenton, I., Lazarou, L. P., Davies, P., 
MacDonald, M. E., Gusella, J. F., Harper, P. S., and Shaw, D. J. (1993) Relationship 
between trinucleotide repeat expansion and phenotypic variation in Huntington’s 
disease. Nat Genet 4, 393–397. 
Appendix | 128  
 
(30) Andrew, S. E., Paul Goldberg, Y., Kremer, B., Telenius, H., Theilmann, J., Adam, 
S., Starr, E., Squitieri, F., Lin, B., Kalchman, M. A., Graham, R. K., and Hayden, M. R. 
(1993) The relationship between trinucleotide (CAG) repeat length and clinical features 
of Huntington’s disease. Nat Genet 4, 398–403. 
(31) Ross, C. A., Poirier, M. A., Wanker, E. E., and Amzel, M. (2003) Polyglutamine 
fibrillogenesis: The pathway unfolds. Proc Natl Acad Sci USA 100, 1–3. 
(32) Wetzel, R. (2012) Physical chemistry of polyglutamine: Intriguing tales of a 
monotonous sequence. J Mol Biol 421, 466–490. 
(33) Legleiter, J., Mitchell, E., Lotz, G. P., Sapp, E., Ng, C., DiFiglia, M., Thompson, L. 
M., and Muchowski, P. J. (2010) Mutant Huntingtin Fragments Form Oligomers in a 
Polyglutamine Length-dependent Manner in Vitro and in Vivo. J Biol Chem 285, 14777–
14790. 
(34) Lajoie, P., and Snapp, E. L. (2010) Formation and Toxicity of Soluble 
Polyglutamine Oligomers in Living Cells. PLoS ONE (Chirico, G., Ed.) 5, e15245. 
(35) Nucifora, L. G., Burke, K. A., Feng, X., Arbez, N., Zhu, S., Miller, J., Yang, G., 
Ratovitski, T., Delannoy, M., Muchowski, P. J., Finkbeiner, S., Legleiter, J., Ross, C. A., 
and Poirier, M. A. (2012) Identification of Novel Potentially Toxic Oligomers Formed in 
Vitro from Mammalian-derived Expanded huntingtin Exon-1 Protein. J Biol Chem 287, 
16017–16028. 
(36) Kim, Y. E., Hosp, F., Frottin, F., Ge, H., Mann, M., Hayer-Hartl, M., and Hartl, F. U. 
(2016) Soluble Oligomers of PolyQ-Expanded Huntingtin Target a Multiplicity of Key 
Cellular Factors. Molec Cell 63, 951–964. 
(37) Drombosky, K. W., Rode, S., Kodali, R., Jacob, T. C., Palladino, M. J., and Wetzel, 
R. (2018) Mutational analysis implicates the amyloid fibril as the toxic entity in 
Huntington’s disease. Neurobiol Dis 120, 126–138. 
(38) Pieri, L., Madiona, K., Bousset, L., and Melki, R. (2012) Fibrillar α-Synuclein and 
Huntingtin Exon 1 Assemblies Are Toxic to the Cells. Biophys J 102, 2894–2905. 
 
A8. Brief Overview of Additional Information for Instructors 
 The material following this manuscript is a collection of the key components of 
the Supporting Information document. Grading rubrics, questionnaires, student 
manuals, equipment lists, CAS registries and protocols were not included for 
conciseness. Sections included in the lab summary and instructor notes contain 
important details to aid in the execution of the new lab, including adaptations and 
troubleshooting tips collected in several semesters of teaching this new laboratory 
exercise here at West Virginia University for biochemistry undergraduate students.  
A8.1 Lab Summary for Instructors 
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Huntington disease (HD) is a fatal neurodegenerative disorder characterized by 
psychiatric symptoms, cognitive degeneration and motor instabilities.1  A mutation in the 
huntingtin gene caused by a CAG trinucleotide repeat results in a polyglutamine (polyQ) 
expansion in the translated huntingtin protein (htt). This polyQ expansion spurs htt 
aggregation into fibrils and ultimately into intracellular proteinaceous inclusions.2, 3  
Disease onset is directly correlated with polyQ length where 35-39 repeats may result in 
disease, 40-60 repeats result in adult onset, and repeat lengths greater than 60 are 
observed in juvenile disease onset.2  Further, there is increasing evidence that htt 
aggregation may be associated with disease progression and severity, suggesting a 
larger need for research exploring aggregate formation. 2, 3   
Novel strategies that directly target the HD gene and prevent production of the 
toxic mutant htt are being investigated. One current strategy involves an antisense 
oligonucleotides (ASO)-based RNase activation system via spinal injection to HD 
patients.4 While successful, HD progresses slowly, and this treatment becomes 
expensive if prolonged.  Additionally, protein misfolding and abnormal htt can interfere 
with several cellular processes, including cell trafficking.1,2  This presents several 
challenges not only for obtaining cost-effective treatments but in understanding the 
complete mechanism of the disease progression.5 Investigation into physiologically 
relevant or less invasive therapeutic drug targets exploring htt folding remains a 
necessary and interesting topic of investigation.  
As an undergraduate student, the independent use of advanced instrumentation 
is not always a possibility due to budgetary limitations and the restrictions caused by a 
scheduled laboratory period, which greatly limits individualistic exploration and critical 
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thinking.  These limitations can be modified if the student participates in undergraduate 
research; however, this is not always a possibility for all students. Thus, we have 
developed a laboratory experiment where it is now possible to expand protein growth 
and purification methods to additional proteins that have otherwise been underutilized in 
an undergraduate biochemical setting through modifications made in the laboratory 
timeline.  Specifically, students will complete experimental preparative methods (E. Coli 
growth, protein purification, etc.) that mirror advanced protocols completed in 
biochemical research through guided-inquiry and then complete independent 
experimentation with the htt protein quantifying amyloid formation and prevention using 
macromolecular crowders.   These technical experiences are relevant in a broader, real 
world context. For example, high throughput assays in plate format are a common 
method of screening for potential therapeutics, which relies on many of the design 
principles and data analysis employed in this laboratory experiment. 
Time and curriculum level 
Students should perform the experiment in an advanced laboratory course after 
they have been introduced to basic biochemistry techniques and lab practices; skills 
and topics relating to protein expression and purification, kinetics, instrumentation, and 
critical thinking will be utilized.  The laboratory experiment combines aspects of 
biochemistry and biophysical chemistry, and therefore can be utilized for several topics 
of discussion in biochemistry or physical chemistry courses. Completion of this 
laboratory experiment should occur during lectures that include topics of protein 
expression, protein structure/folding, spectroscopic analytical procedures, and kinetics. 
In total, this experiment requires six, three-hour laboratory sessions. Students work in 
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larger groups during experimentation for four, three-hour sessions, and two, three-hour 
laboratory sessions for oral and written scientific presentations with emphasis on 
developing advanced written and oral communication skills required for upper-level 
education and STEM careers. 
Procedures, techniques, and concepts presented 
During this experiment, students will utilize advanced laboratory techniques to 
determine the effects of macromolecular crowders on htt aggregation kinetics. After 
preparing solutions, such as lysogeny broth (LB) and buffers, students express htt-
exon1 containing an aggregation prone polyQ domain as a GST-fusion protein in 
Escherichia Coli (E. coli). Once optimum density of E. coli is confirmed in the large 
batch inoculations through optical density measurements, protein expression is induced 
via isopropyl-β-D-thiogalactoside (IPTG).  The cells are then washed and harvested as 
pellets via centrifugation. For purification, these pellets are re-suspended in buffer and 
lysed by treatment with lysozyme followed by probe sonication. Cellular debris is 
pelleted and discarded. The cell lysate, which contains the fusion protein, is diluted with 
buffer and loaded onto a prepared glutathione-S-transferase (GST)-based affinity spin 
column for purification via centrifugation.  Upon completion, protein concentration is 
preliminarily determined by a Bradford assay, using a  standard curve generated with 
bovine serum albumin (BSA) standards. The purified protein is dialyzed for 48 hours at 
4℃, with two dialysis buffer exchanges.  The concentration of the dialyzed protein is 
determined using the Bradford assay; however, the purified protein usually needs to be 
concentrated via centrifugal concentrators prior to use in aggregation assays.   
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Students will also prepare thioflavin T (ThT) stocks and several macromolecular 
crowder solutions for testing; they will determine the amount of protein per well that is 
needed for analysis in addition to calculating the appropriate concentrations of thioflavin 
T and crowders. Students then plan and prepare their samples in triplicate using a 96-
well plate and complete kinetic testing via ThT fluorescence using a microplate reader. 
Once completed, students analyze and present their finding to their peers.   
Performing this laboratory experiment provides students with an opportunity to 
utilize important upper level laboratory techniques such as protein expression and 
purification, affinity-based column chromatography, and fluorescence-based assays. 
These experiments enable the student to conceptualize how a protein such as htt 
functions and is analyzed. Students also recognize how simple spectroscopic 
techniques can be efficiently used to monitor the progress of purification and determine 
an unknown concentration of a protein. Students can compare htt aggregation in the 
presence of macromolecular crowders, providing first-hand experimental knowledge of 
the potential impact of the intracellular crowded environment on htt. This laboratory lies 
at the interface between biology and physical chemistry, an important interdisciplinary 
field to which many students are not exposed, particularly in a laboratory setting. 
Additionally, students become familiar with useful data analysis and presentation 
techniques that will be advantageous in advanced STEM educational programs and 
careers. 
Usefulness of experiment 
This laboratory will be useful for illustrating principles of biochemistry and 
biophysical chemistry, including protein expression, purification, and aggregation. 
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Protein purification and aggregation is monitored through analytical techniques, 
including spectroscopic and fluorescence-based assays. The hands-on experience that 
this laboratory experiment provides conceptualization of how these simple techniques 
can be applied to understanding relevant, biochemical phenomena, e.g. toxic protein 
aggregation. Additionally, students gain experience using a microplate reader to 
kinetically monitor aggregation and investigate how molecularly crowded environments 
that mimic the cytosol can influence this process.  Further, using a disease-relevant 
protein such as htt provides real world relevance and a greater appreciation of amyloid 
diseases. Students gain a greater understanding of the complete, fundamental process 
of protein expression and purification followed by application of the obtained protein in 
an assay that mimics exploratory laboratory research that one would encounter in 
industry or in academic research labs.  
Summary of student evaluations 
Student evaluations were completed following each week of experimentation with 50 
student participants spanning two semesters.  From the results of the evaluations, most 
students did not have extensive experience working in a research laboratory nor did 
most complete anything like the weekly experimentation in previous coursework or 
research experiences.   
Common responses to both protein expression (Week #1) and protein purification 
(Week #2) experimentations included “the experiment included components never done 
before in other graded labs like stock preparation” and “this lab was good to learn about 
lab prep work and what actually goes into prepping for experiments as a whole”.  
Throughout the protein purification process (Week # 2), students valued the use of 
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“multiple higher-level instruments” and techniques for completing the experiment and 
“learning multiple things in a lab period that were touched upon in lecture or in the past 
coursework”. Students also reported enjoying group work, which “allowed open 
communication and collaboration” as the experiment was being completed. One 
comment indicated that it was interesting to learn a biochemical approach to column 
chromatography when students are usually only exposed to a version of it in organic 
chemistry.  
The Excel workshop (Week #3) reported an average of 76% of students who valued the 
learning experience, and an average of 95% of students suggested it should be 
continued in future semesters. Students enjoyed the “scientific approach to excel”, 
including the ways to “create data plots that resemble those seen in literature” and 
appreciated tips on how to simplify data analysis.  
Week #4 of experimentation, which consisted of independent experimental design and 
implementation, showed students overall enjoying the increased hands-on working 
opportunities; students also valued the heighten anticipation of completing their 
designed experiment and seeing how the individual weekly laboratories were applied to 
that final design. Student data indicated an average of 82% of students enjoying the six-
week long experiment overall as well as an average of approximately 80% of students 
enjoying each week individually. 
A8.2 Instructor Notes 
Pre-laboratory assignment 
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It is recommended that students complete Experiment # 0 prior to the first three-
hour laboratory session.  Completing this experiment is optional; however, it is 
suggested for students to practice making biological solutions that are not 
conventionally generated in a typical undergraduate laboratory course.  Further, 
completing this experiment will reduce laboratory time, ensuring completion of the htt 
laboratory experiment, and provide students with an obvious example of how 
preparation is essential in biochemical research.    
Alternative experiments 
 This laboratory experiment is advantageous in that it can be readily adapted to 
investigate other relevant intracellular components.  For example, using the ThT assay, 
students could explore the use of other physiologically relevant macromolecular 
crowder molecules or small molecules, such as epigallocatechin gallate (EGCG), 
curcumin and rizuole. Potential therapeutic drug screenings could also be completed 
where students could compare and differentiate their findings on different drug targets. 
Another simplistic laboratory assay, such as polydiacetylene assay (PDA), could be 
used to study the effects of crowders, small molecules or potential drugs on htt binding 
to lipids. This assay may possibly be expanded further by exploring different lipid 
systems or incorporating lipids into the ThT assay. Depending on instrumentation and 
skill level of students, variation of instrumentation in the final experiment can occur. 
Circular dichroism (CD), atomic force microscopy (AFM), solid state nuclear magnetic 
resonance (ssNMR), and scanning electron microscope (SEM) are all examples that 
can be used to modify the experiment. For example, AFM can be used to study the 
morphologies of various aggregates produced and can complement kinetic assays 
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using similar experimental conditions. Other techniques including immunohistology 
experiments (Western blots, slot and dot blots) can also be used to identify different 
protein aggregates. 
Laboratory preparation 
Students can work in large groups with individual students taking turns 
completing tasks at various stages throughout each week of experimentation. Students 
should be provided with appropriate equipment and chemicals. 
Solution preparation 
Solution preparation and some procedural steps will need to be completed 
outside of the scheduled laboratory period by the instructor or teaching assistant. 
Several salt, bleach and buffer solutions will need to be prepared as described. During 
Week #1, E. coli. large batch inoculations from the overnight culture should be started 
and close to the appropriate optical density (OD) prior to the start of the first laboratory 
session. Depending on the polyQ repeat length used, the incubation period will need to 
be started 24 hours in advance with the expression step occurring between two and four 
hours prior to the start of the lab session. In Week #2, the protein should be dialyzed for 
48 hours with aliquots of dialysis buffer being replaced twice.   Note: The protein 
prepared by students will be useable for up to 10 days, however, ideal use would be 
within 5-7 days.  
Multiple htt samples can be combined to generate mock data for use in Week #3 
experimentation. Additionally, a large quantity of protein should be purified three days 
prior to Week #4 laboratory session to ensure freshness and prevent seeding.   If 
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preferred, a larger sample of protein could be purified using a liquid chromatography 
(LC) system or multiple purifications could be completed and combined using the spin 
column purification method as described in Week #2. 
Instrumental instructions 
Prior to starting each three-hour laboratory session, instructors should turn on the 
refrigerated centrifuge and plate reader one to two hours prior to the experiment to 
ensure appropriate temperature equilibration.  UV-Vis spectrophotometer, sonicator, 
and bath sonicator can all be turned on during the experiment as they do not have 
lengthy start up times. Additional details are outlined in the experimental procedures 
each week. 
Tips for success 
Notes are provided to students to assist in proper experimental completion; 
however, some additional areas where difficulties may occur should be announced to 
students. Starting with the first week, encourage students to think of how the 
instrumentation and weekly experiment applies to their overall experimental objectives. 
Participation by each student should be monitored during the laboratory sessions, as 
students may not be self-motivated, interested in teamwork, or have no experience in 
gradate-related research labs.  Encouragement and deeper conceptual inquiries with 
the instructor are encouraged, as these interactions are more representative of a 
research setting and helps to promote the desired self-guided approach; opportunities 
to discuss the written laboratory reports and oral presentations prior to submission and 
in-class presentations are also suggested.  
Appendix | 138  
 
Troubleshooting 
 Special care should be taken with some experimental protocols. For example, 
the probe sonicator has a very delicate tip that is easily damaged. Students should be 
encouraged to handle the probe sonicator gently and monitor the protein consistency for 
any necessary adjustments in probe wattage. Additionally, if the concentration results in 
a lower yield than expected, procedural modifications can be made by reducing the 
number of wells to two instead of three or reducing the protein concentration per well. 
This ensures useful data will be achieved and demonstrates the unpredictability of 
scientific research.  
Adapting This Experiment 
Htt is useful at demonstrating additional biochemistry topics, such as protein 
structure and aggregation mechanisms, depending on instrumentation and desired 
difficulty level. If htt is not available, the protein could easily be substituted with β-
amyloid or α-synuclein peptides. These peptides can be ordered commercially but 
would not require purification, which would eliminate cell growth and purification from 
the experimental procedure.  However, this change could allow for the introduction of 
other experimental methods and instrumentation involved in peptide preparation, 
including lyophilizers and vacuum pumps.   
Students could prepare the stock solutions required for the experiment, including 
1 M Na2PO4, 1 M NaH2PO4, 5 M NaCl, 1 M Tris (pH 7) and a 10% bleach solution; this 
would accompany in-lab preparation of purification solutions such as dialysis buffer, 
buffer A, buffer B and aggregation buffer.  
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Students should be cognizant of experimental procedures completed outside of 
the scheduled laboratory period, such as dialysis or expression steps. If available, 
students can purify larger quantities of the protein using a low-pressure liquid 
chromatography (LC) system, which would provide protein for multiple experimental 
comparisons on one microfluorescent plate. Comparisons of similar or different targets 
could be completed with students generating a scientific case for why their target should 
be explored further.  
Calculations could be removed or added to modify the difficulty level during each 
week of experimentation.  Additionally, a more in-depth literature search of htt along 
with a chosen assay could be conducted. 
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